

Consensus document

Diagnosis and treatment of urinary tract infection. Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

Marina de Cueto^a, Luis Aliaga^b, Juan-Ignacio Alós^c, Andres Canut^d, Ibai Los-Arcos^e, Jose Antonio Martínez^f, Jose Mensa^f, Vicente Pintado^g, Dolors Rodriguez-Pardo^e, Jose Ramon Yuste^h, Carles Pigrau^e.

^aUnidad Clínica intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Sevilla. Spain.

^bUnidad de Gestión Clínica de Medicina Interna, Hospital Universitario Unificado de Granada Granada. Spain

^cServicio de Microbiología, Hospital Universitario de Getafe, Getafe. Spain.

^dServicio de Microbiología, Hospital Universitario de Alava, Vitoria-Gasteiz. Spain.

^eServicio de Enfermedades Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona. Spain.

^fServicio de Enfermedades Infecciosas, Hospital Clinic-IDIBAPS, Barcelona, Spain.

^gServicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, Spain.

^hÁrea de Enfermedades Infecciosas, Clínica Universidad de Navarra, Pamplona. Spain.

ABSTRACT

Urinary tract infection (UTI) remains one of the most common infectious diseases encountered in the outpatient setting. Most patients are young healthy sexually active women with uncomplicated UTI. Most women do not require extensive evaluation and can be safely managed as outpatients with oral antibiotics. Antibiotic treatment is empirically established based on the local susceptibility pattern of *Escherichia coli*, which is the causative agent of more than 80% of these infections. Other major clinical problems associated with UTI include asymptomatic bacteriuria and patients with complicated UTI. Complicated UTIs are a heterogeneous group associated with conditions that increase the risk of acquiring infection or failing therapy. Distinguishing between complicated and uncomplicated UTI is important because it influences the initial evaluation, choice and duration of antimicrobial therapy. Diagnosis is especially challenging in the elderly and in patients with indwelling catheters. The increasing prevalence of resistant uropathogens, including extended-spectrum β -lactamases and carbapenemase-producing *E. coli* and *Klebsiella pneumoniae*, and other multidrug-resistant Gram-negative organisms, further compromises treatment of both complicated and uncomplicated UTIs.

The aim of these clinical guidelines is to provide a set of recommendations for improving the diagnosis and treatment of UTI in accordance with the latest published evidence and local resistance patterns.

Keywords:

Urinary tract infection

Asymptomatic bacteriuria

Acute cystitis

Acute pyelonephritis
Recurrent urinary tract infections
Catheter-associated urinary tract infection

Diagnóstico y tratamiento de las infecciones del tracto urinario. Guía de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)

RESUMEN

Las infecciones del tracto urinario (ITU) siguen siendo una de las enfermedades infecciosas más frecuentes del ámbito ambulatorio. La mayoría de infecciones del tracto urinario son infecciones no complicadas que se presentan en mujeres jóvenes, sexualmente activas. En la mayoría de los casos no se requieren pruebas diagnósticas complementarias y se pueden tratar ambulatoriamente de forma segura con antibióticos por vía oral. El tratamiento antibiótico se establece de forma empírica, de acuerdo con el patrón local de sensibilidad de *Escherichia coli*, que es el agente causal de más del 80% de estas infecciones. La bacteriuria asintomática (BA) y las ITU complicadas son otras formas de presentación de la ITU. Las ITU complicadas son un grupo heterogéneo de enfermedades que incrementan el riesgo de adquisición de la infección o de fracaso del tratamiento. La distinción entre ITU complicada y no complicada es fundamental para decidir la evaluación inicial del paciente, la elección del antimicrobiano y su duración. El diagnóstico es especialmente difícil en ancianos y en pacientes con sondaje permanente. El incremento de cepas resistentes a los antibióticos, especialmente *E. coli* y *Klebsiella pneumoniae*, productoras de betalactamasas de espectro extendido y de carbapenemasas y de otros gramnegativos multirresistentes, dificulta la elección del tratamiento de las ITU complicadas y no complicadas.

El objetivo de esta guía clínica es proporcionar recomendaciones basadas en la evidencia para mejorar el diagnóstico y tratamiento de las ITU de acuerdo con la última evidencia publicada.

Palabras clave:

Infecciones del tracto urinario
Bacteriuria asintomática
Cistitis aguda
Pielonefritis aguda
Infecciones recurrentes del tracto urinario
Infecciones urinarias asociadas con el sondaje vesical

Introduction

Justification and opportunity

Urinary tract infection (UTI) is one of the most common clinical problems in both the community and healthcare-associated settings. Community-acquired uncomplicated UTIs (uUTI) are particularly common among women, the vast majority of whom experience at least one episode of infection in their lifetime. A significant subset (25-40%) of women also develop recurrent urinary tract infections (rUTI), with multiple infections that recur over months, or years, in some cases^{1,2}. Other relevant clinical problems associated with UTI include

asymptomatic bacteriuria (AB) and patients with complicated urinary tract infection (cUTI)^{2–4}. Nosocomial UTI (generally a reflection of catheter-associated infections) constitutes about 20–30% of all hospital-acquired infections and are common sources of nosocomial bacteremia^{2,4}.

One of the most important factors impacting the management of UTI in recent years has been the emergence of antimicrobial resistance among uropathogens, particularly isolates causing community-acquired UTI. Numerous studies have been published examining rates of *in vitro* resistance among uropathogens in individual institutions or geographic areas. These studies include a variety of patient populations, such as inpatients, outpatients, and people with normal or abnormal urinary tracts. Taken together, these studies demonstrate that *in vitro* resistance is a significant problem, not only in nosocomial complicated UTI, where it has traditionally been recognized as such, but also in community-acquired, uncomplicated UTIs that have typically been simple to treat. Although at the moment antimicrobials can generally ensure the successful treatment or prevention of UTI, the emergence of antimicrobial resistance among uropathogens may soon limit our ability to do so^{5–7}.

The judicious use of antibiotics and novel non-antimicrobial-based products for preventing UTIs are important strategies to help slow the progression of resistance.

All the above reasons illustrate how variable and complex these infections are, which is why the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica) requested a panel of experts to provide an update on many of the issues involved, including the aetiology, microbiology, prevention, diagnosis, and treatment of various UTI syndromes. The related topic of prostatitis falls outside the scope of these guidelines.

Aims

The main objective of this Consensus Statement is to provide an ensemble of recommendations for improving the diagnosis and treatment of different UTI syndromes in accordance with the latest evidence published.

Methods

Two authors (CP, MC) coordinated the contributions of all other authors (infectious diseases specialists, internal medicine physicians and clinical microbiologists), who appear in alphabetical order. The present statement was written following SEIMC guidelines for consensus statements (www.seimc.org), as well as *Agree Collaboration* (www.agreecollaboration.org) recommendations for evaluating the methodological quality of clinical practice guidelines. Over various meetings, the authors selected a set of questions designed to form the basis of the document. Their recommendations are based on a systematic critical review of the literature including, when necessary, the opinion of experts, who are SEIMC members. Their recommendations have been adjusted according to the scientific evidence available (Appendix 1). All the authors and the coordinators of the statement have agreed on the contents and conclusions of the document. Before final publication, the manuscript was made available online for all SEIMC members to read and to make comments and suggestions.

Definitions

A UTI is defined as a combination of clinical features and the presence of bacteria in the urine. Acute uUTI includes episodes of acute cystitis (AC) or lower UTI, and acute pyelonephritis (APN) occurring in otherwise healthy individuals, most of whom are women with normally functioning urinary tract systems^{1,2,8}. Complicated UTI refers to UTI in patients with underlying predisposing conditions, whether medical, functional, or anatomical, or who have been recently hospitalized, which increases the risk of initial infection and recurrence or reduces the effectiveness of therapy. The most commonly found predisposing conditions considered to render a UTI complicated include diabetes, neurogenic bladder, indwelling catheter use and urinary obstruction of any cause^{2,4,8}.

In lower UTI, the presence of a resistant microorganism alone is not a sufficient criterion for a UTI to be considered complicated, because, with appropriate antimicrobial therapy, the outcome of the illness ought not be affected. Nonetheless, the presence of risk factors for resistance encourages us to be cautious in the management of APN patients and not to discharge the patient early until the antimicrobial susceptibility results have been received.

Although many UTIs in men and the elderly are complicated, a patient who is male or elderly does not in itself necessarily make UTI complicated; some men and elderly individuals can be considered as having uUTI and be treated accordingly⁹. Distinguishing between uncomplicated and complicated UTI is therefore important because it influences the initial evaluation, the location of treatment (outpatient versus inpatient setting), and the selection and duration of antimicrobial therapy^{2,10}.

Asymptomatic bacteriuria (AB) is the occurrence of bacteria in the urine without causing symptoms. AB is common in the population group that experiences symptomatic UTI (sUTI), but is of clinical significance mainly in pregnant women or individuals who undergo invasive genitourinary procedures³.

General considerations

Etiology

Most cases of uUTI are due to a single bacterial pathogen, with *E. coli* isolated in 75-95% of cases. Another 5% to 15% of cases may be due to *Staphylococcus saprophyticus* (which is mainly associated with uncomplicated AC), while the remaining cases are usually due to other Enterobacteriaceae such as *Proteus mirabilis* and *Klebsiella pneumoniae*. In uncomplicated APN, the causative agents are similar to those that cause uncomplicated AC; in over 80% of cases, the causative agent is *E. coli*^{5,6,11}.

The etiology of UTI is modified by factors such as age, sex, diabetes mellitus, urinary tract obstruction, spinal cord injuries (neurogenic bladder) and urinary catheterization, among others, which are all possible conditions of cUTI. The etiology of cUTI is usually more varied and less predictable than uUTI. Microorganisms rarely implicated in UTI in a healthy population are able to cause UTI in patients with anatomical, metabolic and immune disorders. Exposure to antibiotics and a history of hospitalization also determine differences in the etiologic profile. In rUTI, especially cUTI, while *E. coli* remains the main causal agent, there is a significant increase in the relative frequency of infection by *Proteus* spp, *Pseudomonas aeruginosa*, *K. pneumoniae*, *Enterobacter* spp, enterococci and even yeast. Furthermore, there is the possibility of mixed infections in which two or more organisms are involved at the same time^{4-6,12}.

Epidemiology and risk factors

The incidence of UTI is highest in young women, the vast majority of whom experience at least one infection during their lifetime^{1,2}. Other groups at increased risk for UTI, as well as complications of UTI, include infants, pregnant women, the elderly, and individuals with diabetes, immunosuppression, spinal cord injuries, indwelling catheters or urologic abnormalities^{2,8,10}.

Proven risk factors for UTI in young women are previous episodes of cystitis, recent sexual activity, and the use of spermicidal agents during intercourse. The odds of UTI increase by a factor of 60 in the first 48 hours after sexual intercourse. Additional risk factors have been shown to be significant in specific subgroups of the population. Postmenopausal women, cystoceles, urinary incontinence, and prior urologic or genital surgery are significant risk factors for recurrent cystitis. In elderly women, the risk of UTI increases with age, particularly in those with impaired voiding, and is also higher in patients with diabetes.

The prevalence of UTI is low in adult men (0.1% or less) until the later years, when it rises. The increase in UTI frequency in older men is related to prostatic disease and the resultant instrumentation. Other risk factors for the development of UTI in men include insertive anal sex, lack of circumcision, and renal stone disease^{2,8-10}.

Clinical impact of resistance

In recent years, *E.coli* has shown increasing resistance to several first-line antibiotics and has become a worldwide problem^{5,6}. Since the resistance patterns of *E. coli* strains causing uUTI demonstrate considerable geographic variability, specific recommendations for treatment may not be universally applicable to all countries. Recommendations of first-line treatment agents should be supported by up to date local epidemiological data^{5-7,11}.

In Spain the results of recent studies^{6,7} indicate a high prevalence (>50%) of resistance of *E. coli* to aminopenicillins (ampicillin and amoxicillin) and co-trimoxazole (COT) (20-35%). Also, from the beginning of the 1990s we have witnessed a continuous increase in the resistance of uropathogens to fluoroquinolones (FQs), which currently ranges 10-30%. In the ARESC study 26.1% of *E. coli* strains were resistant to nalidixic acid, a marker of the potential future level of FQs resistance, 11.5% with high-level resistance and 14.6% with low-level resistance⁵.

Rates of resistance to amoxicillin/clavulanate (AMC) and cefuroxime (CXM) have had a slow but steady increase, and currently 25% of the strains are resistant or intermediate to these antibiotics in retrospective studies^{6,7}. Associated resistance involving β -lactams, COT and FQs is common^{5,6}.

Antibiotics employed specifically in UTI, such as fosfomycin (FOF) and nitrofurantoin (NIT) exhibited low levels of resistance and over 95% of *E. coli* strains isolated in both recurrent and non-recurrent UTI were susceptible^{5,6}.

In many laboratory-confirmed infections, resistance correlates with clinical and microbiological failure, but there are few studies examining clinical outcome in UTI with resistant organisms, since patients with resistant organisms are usually excluded from clinical trials. In two studies involving lower UTI, resistance to COT was associated with lower rates of bacterial eradication, higher rates of clinical failure and reconsultation than when susceptible organisms were involved^{13,14}.

In uncomplicated APN, Talan *et al*¹⁵ observed that women infected with strains resistant to COT showed higher rates of bacteriological failure than those susceptible to COT (50% vs. 4%). These results indicate that in women with either APN or AC, infection with a COT-resistant organism predicts clinical failure if COT is used for treatment. There are insufficient data to determine how other antibiotics perform in women infected with resistant uropathogens.

In the case of COT, clinical and mathematical modelling studies consistently suggest a resistance prevalence of 20% as the threshold beyond which the agent is no longer recommended for empiric treatment of AC, although there is insufficient evidence of other antibiotics to recommend thresholds for alternative empiric agents. In addition, the recommended threshold of 10% fluoroquinolone resistance for using an alternative agent for APN is based on expert opinion, since there is no supporting evidence from controlled therapeutic trials¹.

The empiric choice of particular antibiotics to treat very common diseases such as UTI should also consider their ecological impact. The use of broad-spectrum antibiotics is associated with selection of multidrug-resistant (MDR) bacteria, *Clostridium difficile*-associated diarrhea and fungal vaginitis.

RECOMMENDATION

1. An antimicrobial agent is not recommended for empiric treatment of urinary tract infections if local resistance prevalence is over 20% for cystitis (B-II) or 10% for pyelonephritis (C-III).

What microbiological and clinical data should be used to guide empiric treatment of UTI?

To interpret microbiological data on resistance, it should be borne in mind that the data published in many retrospective and even prospective microbiological studies is likely to show bias, because microbiology laboratories tend not to receive many urine samples for uUTI (which are treated empirically as recommended and generally do well), but do receive a significant percentage of urine samples from recurrent and cUTI, where the most resistant bacteria are isolated. Extrapolating data from hospital or cUTI pathogens to uUTI pathogens has its limitations since resistance tends to be overestimated¹⁶.

In a retrospective study conducted in Spain that included cases of cUTI and uUTI, rates of resistance to FQs for lower UTI were higher than in a prospective study, also conducted in Spain, which included only cases of uUTI^{6,7}, and resistance rates varied significantly by sex, age and geographic location, which may be partly related to different antibiotic prescription patterns across the various communities. In another Spanish study where a urine culture was requested for all suspicious cases of UTI, it was observed that for cUTI, resistance to FQs was 19.5% to ciprofloxacin (CIP) and 25.6% to nalidixic acid, while for uncomplicated UTI, it was 8.5% and 14.6% respectively; these differences were statistically significant. There were also significant differences of FQ resistance by sex, age and previous antibiotic treatment¹⁷.

In a study involving women with uUTI confirmed by culture, it was found that resistance to trimethoprim (TMP) was much less frequent than had been predicted based on the global data of urine cultures sent to the laboratory, 14% versus 24-27%¹⁴.

RECOMMENDATION

1. Studies of the susceptibility of uropathogens in the community tend to overestimate resistance rates. To guide empiric treatment, susceptibility and clinical data (type of UTI (uncomplicated versus complicated), sex, age and previous antibiotic therapy) should be considered (A-II).

Diagnosis

When is a urine culture necessary for the diagnosis of uncomplicated cystitis?

Enterobacteriaceae are the main bacteria isolated in AC, which has a characteristic clinical presentation^{1,2,18}. A meta-analysis found that women with at least 2 symptoms of UTI (dysuria, urgency, or frequency) and no symptoms suggesting vaginitis or cervicitis, such as vaginal discharge or irritation, was more than 90% likely to have AC¹⁹.

A urine culture is generally not required for suspected cases of uncomplicated AC because the constellation of symptoms is sufficiently diagnostic, the spectrum of causative organisms and antimicrobial susceptibility profiles are predictable and also because the culture results become available only after the therapeutic decisions need to be made. A randomized trial of management strategies in women with symptoms of AC found that obtaining a urine sample for dipstick testing or culture had no advantages associated with symptom scores or time to reconsultation when compared with immediate empiric therapy²⁰. Thus, the current recommendation therefore is to initiate empiric treatment on the basis of symptoms alone and without a pre-therapy urine culture^{18,20–24}. The choice of antibiotic is generally determined by the local susceptibility pattern of *E. coli* and the patient's history of antibiotic allergy^{21–23}.

In certain cases a pre-treatment urine culture may be indicated, in young women, for example, when the diagnosis is not clear from her history and physical examination, or in outpatients with rUTI, who have experienced treatment failure, or have cUTI^{24,25}, as previously defined. Although *E. coli* remains the most common pathogen isolated in complicated AC, it is found in only 50% of cases. Other Enterobacteriaceae, such as *Proteus* spp, *Klebsiella* spp, *Serratia* spp, *Providencia* spp, as well as *P. aeruginosa*, enterococci, staphylococci and fungi may also play an important role, depending on the underlying conditions^{24,25}. Furthermore, the organisms that cause complicated AC are more likely to be resistant to the oral antimicrobials most frequently recommended for uncomplicated AC^{10,24,25}. One fluoroquinolone-resistant, extended-spectrum beta-lactamase (ESBL)-producing strain in particular, *E. coli* sequence type 131 (ST131), has emerged globally as a major cause of UTI^{10,26,27}. Culture data are especially important for switching therapy in patients who fail to respond to empiric therapy because of infection with a resistant uropathogen, and for switching when appropriate to narrower-spectrum agents^{1,10,20,24,25}.

Some authors consider all UTIs in postmenopausal women to be complicated, although it is reasonable to consider them uncomplicated if the woman is healthy, ambulatory, and not institutionalized¹. Urine culture is also considered standard of care in pregnant women^{1,3,19,22,24,25,28}.

A routine post-treatment culture is not indicated for asymptomatic women following treatment for AC because the advantages of detecting and treating AB in healthy women has been demonstrated only for pregnant women and before urologic instrumentation or surgery.

Post-treatment culture only should be obtained if symptoms persist or recur soon after treatment³.

RECOMMENDATIONS

1. In women with uncomplicated cystitis, empiric treatment should be initiated on the basis of symptoms alone. A urine culture is generally not necessary (E-I).
2. A pre-treatment urine culture should be obtained when the diagnosis is not clear from the history and physical examination, when the episode represents an early symptomatic recurrence, when there is reason to suspect antimicrobial resistance or the patient's therapeutic options are limited due to medication intolerance (A-II).
3. Routine post-treatment cultures are not indicated for asymptomatic women following treatment for cystitis (E-II) and should only be obtained if symptoms persist or recur soon after treatment (A-II).

Are blood cultures useful in the management of patients with acute pyelonephritis?

Blood cultures are considered to be an important tool for evaluating and managing patients with suspected bacterial infection, although, in the case of APN, detecting the implicated pathogen in a urine culture has a high diagnostic yield^{29–31}. Several, mostly retrospective, studies have investigated the utility of blood cultures in patients with complicated and uncomplicated APN and they have all generally supported the conclusion that blood cultures have limited clinical value and seldom vary from urine culture results^{29–33}. In a prospective study in a Spanish hospital, 25.2% of blood cultures from 583 women with uncomplicated APN were positive. Only 2.4% of isolates from a blood culture differed from those from the corresponding urine culture, and not a single case required a change of antimicrobial therapy based on blood culture results³². In a retrospective study of 246 patients with APN, there were 83 (31%) bacteremic patients. Positive blood cultures were concordant with urine cultures in over 95% of cases and there were no differences in clinical outcome between patients with or without bacteremia³³. Studies performed on pregnant women with APN reached the same conclusions^{34,35}.

Discordant results have most frequently been observed in patients receiving antibiotic therapy^{36,37}. A study including 800 patients with cUTI from whom both urine and blood cultures were obtained showed that 7% of patients had discordant culture results. Receiving antibiotic therapy at the moment of presentation was associated with a 10.1% risk of having a discordant culture result, compared with 5.4% without antimicrobial treatment. On the basis of these results, the authors recommended collecting both blood and urine cultures in patients receiving antibiotics at the time of hospitalization³⁶.

At present, there is no supporting evidence from randomized controlled trials to evaluate whether a routine blood culture improves the outcome for the management of APN. In the context of uncomplicated APN, blood cultures are rarely clinically useful and seldom vary from urine culture results^{29–33}. Based on the evidence available, the indications for taking blood cultures may be limited to patients with complicated infections, those receiving antibiotics and those with signs of severe sepsis^{32,36,37}.

RECOMMENDATION

1. The available evidence suggests that there is no need to routinely take a blood culture from women with uncomplicated pyelonephritis (E-II). It seems reasonable, however, to obtain a

blood culture from patients with complicated infections, those receiving antibiotics or who have severe sepsis (B-II).

What number of bacteria in urine is considered significant for the diagnosis of UTI?

A microbiological diagnosis of UTI requires an appropriately collected specimen of urine from which one or more uropathogens meeting specific quantitative criteria are isolated.

A quantitative count of $\geq 10^5$ CFU/mL from voided midstream urine was initially proposed as the diagnostic criterion for defining significant bacteriuria as opposed to contamination^{38,39}. Although this criterion is still of general importance for a diagnosis of UTI, there are several exceptions. It is now clear that there is no fixed bacterial count indicative of significant bacteriuria that can be applied to every kind of UTI and all circumstances.

A bacterial count indicating “significant” bacteriuria (the isolate is the likely pathogen) depends on a combination of factors, including the presence or absence of symptoms, the age and sex of the patient, the identity of the uropathogens, and the sampling method^{24,38–42}.

In patients with UTI symptoms, isolation of $\geq 10^5$ CFU/mL of urine in one sample carries a 95% probability of being true bacteriuria. However, in symptomatic women with pyuria, a lower midstream urine count ($\geq 10^2$ CFU/mL) has been associated with the presence of bladder bacteriuria. In such instances, therefore, a finding of $\geq 10^2$ CFU/mL may be indicative of UTI. In one prospective case-control study, “low count” bacteriuria was more frequent among young women with urinary tract symptoms than among asymptomatic controls and a stepwise increase in bacterial counts from 10^2 to 10^5 CFU/mL was significantly associated with increased incidence of symptoms and pyuria. The authors suggested that low-count bacteriuria reflects an early stage of UTI⁴². In daily clinical practice in most microbiology laboratories, the lower detectable limit is $\geq 10^3$ CFU/mL. A more recent study of healthy premenopausal women with uncomplicated AC confirmed that the presence of *E. coli* in midstream urine was highly predictive of bladder bacteriuria, even at very low counts, with a positive predictive value of 93% for growth of $\geq 10^2$ CFU/mL. In contrast, enterococci and group B streptococci isolated from midstream urine at counts of 10^2 – 10^5 CFU/mL, often with *E. coli*, were not found in catheterized samples obtained at the same time and were not predictive of bladder bacteriuria at any colony count⁴³.

In samples obtained by catheterization, in symptomatic women with lower non-catheter related UTI, also a count of $\geq 10^2$ CFU/mL identifies significant bacteriuria^{24,41,44}.

Counts of 10^2 – 10^3 CFU/mL are also acceptable in symptomatic males (because contaminants are unlikely to be present in voided urine), in patients already on antimicrobials, and also with organisms other than Enterobacteriaceae^{24,41,44}. In bladder urine obtained by suprapubic aspiration, any number of bacteria is considered to be significant, although the count will usually be $\geq 10^3$ CFU/mL. Bladder urine may occasionally be contaminated from the urethra, and small numbers of bacteria may be found in aspirated urine from non-infected persons^{24,41,44}.

Colony counts of $\geq 10^4$ CFU/mL are indicative of bacteriuria in women with APN (sensitivity 90% and specificity 90%)^{40,44,45}.

In symptomatic patients with indwelling urethral, indwelling suprapubic or intermittent catheterization, UTI is defined microbiologically as the presence of $\geq 10^3$ CFU/mL of a bacterial species in a single catheter urine specimen or in a midstream voided urine

specimen from a patient whose urethral, suprapubic, or condom catheter has been removed in the previous 48 h⁴.

Most UTI are caused by a single microorganism. Recovery of more than one microorganism may be a result of contamination during collection or may represent polymicrobial infection. A single microorganism is almost invariably present in patient with uncomplicated infection. Patients with cUTI (mainly in patients with indwelling long term urinary catheter) may have multiple organisms in their urine. As many as four or more different species may be recovered from patients indwelling long term urinary catheter. However, there is no standard definition for significant bacteriuria in polymicrobial infections. In the opinion of some experts, no more than two bacterial species should be identified in a urine specimen from a patient with cUTI. The microbiology laboratory should be alerted to the possibility of polymicrobial infection, but if this is not done, the specimen should be informed as “contaminated”⁴¹.

In women, AB should not be diagnosed on the basis of a single urine culture. Two consecutive clean-voided specimens with the same uropathogen at counts of $\geq 10^5$ CFU/mL or one positive urine culture with a positive nitrite test in another sample are required for diagnosis. In men, bacteriuria is defined as a single urine specimen with a uropathogen isolated at a count of $\geq 10^5$ CFU/mL. For the microbiological diagnosis of patients with catheter-associated asymptomatic bacteriuria (CA-AB) and patients with condom catheters, a urine culture is considered positive when the bacterial count is $\geq 10^5$ CFU/mL. These criteria apply only to Enterobacteriaceae. Gram-positive organisms, fungi, and bacteria with fastidious growth requirements may not reach titers of 10^5 /mL in patients with infection, but may fall within the 10^4 to 10^5 /mL range³.

RECOMMENDATIONS

1. Urine samples for culture should be collected in a manner that minimizes contamination (A-II).
2. For symptomatic women, a culture definition for cystitis is $\geq 10^2$ CFU/mL (A-I) of a uropathogen, and for pyelonephritis $\geq 10^4$ CFU/mL (A-II). In non-catheter-related cystitis, counts of $\geq 10^2$ CFU/ml are significant in urine samples obtained by catheterization (B-III).
3. In males with cystitis, a culture of $\geq 10^3$ CFU/mL is considered to be significant (A-III).
4. In women with cystitis, the concomitant isolation of enterococci or group B streptococci with an Enterobacteriaceae in a midstream urine culture has low clinical significance (A-I).
5. In patients with indwelling urethral, indwelling suprapubic, or intermittent catheterization, symptomatic UTI is microbiologically defined as the presence of $\geq 10^3$ CFU/mL of a bacterial species in a single catheter urine specimen or a midstream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48 h (A-III).
6. In bladder urine obtained by suprapubic aspiration, any number of bacteria is considered to be significant (A-II).
7. In women with asymptomatic bacteriuria, two consecutive clean-voided specimens with the same uropathogen at counts of $\geq 10^5$ CFU/mL, or one positive urine culture with a positive nitrite test in another sample, are required for diagnosis (B-II). In men, bacteriuria is defined as a single uropathogen isolated at a count of $\geq 10^5$ CFU/mL (B-III).
8. Asymptomatic bacteriuria in patients with indwelling urethral, indwelling suprapubic, or intermittent catheterization is microbiologically defined as the presence of $\geq 10^5$ CFU/mL of

a bacterial species in a single catheter urine specimen or a midstream voided urine specimen from a patient whose urethral (A-III), suprapubic (A-III), or condom catheter (A-II) has been removed within the previous 48 h.

General aspects of antimicrobial therapy for the treatment of uncomplicated UTIs

The aim of antibiotic treatment of UTI is to inhibit growth and kill bacteria present in the urine, as well as in the bladder and kidney tissues in order to prevent complications, such as abscesses in the urinary tract or the spread of infection to the blood⁴⁶. The primary goal of antibiotic treatment in uUTI is to eradicate the uropathogen rapidly and cure the infection⁴⁷. The treatment of uncomplicated AC due to antibiotic-resistant *E. coli* generally results in the longer duration of local symptoms. Furthermore, in APN, it can progress to sepsis and many patients often need longer hospitalization¹⁶.

Which pharmacokinetic/pharmacodynamics parameters of an antibiotic describe exposure-response relationships in general?

The major indicator of the effect of an antibiotic is the MIC, or minimum inhibitory concentration, which provides information about the antibiotic susceptibility of a pathogen. However, use of MIC values as the only marker of the efficacy of an antibiotic agent may be misleading, since the clinical outcome is determined by complex interactions between the three elements of antibiotic therapy: the host, the microorganism, and the drug. Over the last few years, it has become apparent that the pharmacokinetic (PK) and pharmacodynamic (PD) properties are the major determinants of *in vivo* efficacy of antimicrobial agents.

PK/PD represents the relationship between antimicrobial exposure and the effect of the antimicrobial agent on the microorganism (MIC value). Bacterial killing is best described by the indices incorporating the antimicrobial's PK/PD parameters and by the lowest concentration of antimicrobial required to prevent the growth of the target organism⁴⁸. The PK/PD indices are the length of time a free drug concentration exceeds the MIC ($fT > MIC$) for β -lactams (time-dependent antibiotics); the ratio of the maximum plasma concentration of antibiotic to MIC (C_{max}/MIC) for aminoglycosides and FQs (concentration-dependent antibiotics); and the ratio of the area under the concentration-time curve at 24 hours to MIC (AUC/MIC) for glycopeptides, FQs and aminoglycosides (a combination of the two patterns). These indices can be calculated *in vivo* and *in vitro* using population modeling with Monte Carlo simulations (computer algorithms which give probability distributions through repeated random sampling) and are useful for predicting the probability of target attainment (PTA) at different index thresholds using different dosing regimens⁴⁹. The PK/PD breakpoint is the MIC value considered necessary to achieve a PTA of 90%. The value of 90% for PTA is arbitrary, but is currently accepted. Nevertheless, in UTI, lower doses of antimicrobials have been used with good clinical success.

RECOMMENDATIONS

1. Bacterial killing is best described by indices incorporating the antimicrobial's PK and PD parameters and the minimum inhibitory concentration (MIC), the lowest concentration of the antimicrobial required to prevent the growth of the target organism (B-II).

Are urine-specific breakpoints necessary?

It is conventional not to adjust the breakpoints of most antibiotics used for UTI in order to reduce the complexity of multiple interpretive criteria. Moreover, it is not usually possible to distinguish isolates associated with lower versus upper UTI⁵⁰. There are however some antibiotics, like NIT and FOF, which appear in the CLSI guidelines and are used to treat lower UTI only. In 2014, CLSI created a urine susceptibility breakpoint of ≤ 16 mg/L for the use of cefazolin in uncomplicated UTI due to *E. coli*, *Klebsiella* spp, and *P. mirabilis*. The cefazolin urine breakpoint can also be used to predict the susceptibilities of 7 oral cephalosporins, such as CXM⁵¹.

EUCAST has published several antimicrobial breakpoints that are valid only for isolates from lower uUTI (such as cephalexin, TMP and NIT against Enterobacteriaceae), although none of these agents have breakpoints for isolates from systemic infections. FOF and CXM have separate breakpoints for oral and intravenous formulations, with the oral formulations being for lower uUTI only. In 2014, EUCAST introduced a urinary susceptibility breakpoint for AMC of ≤ 32 mg/L (amoxicillin concentration plus a fixed (2 mg/L) concentration of clavulanic acid) for uncomplicated UTI⁵².

RECOMMENDATIONS

1. Specific susceptibility breakpoints for UTI isolates are recommended (B-III). EUCAST and CLSI have published several breakpoints that are valid only for isolates in uncomplicated urinary tract infections.

Is the antibiotic concentration in serum or urine the most important?

Since there are few PK/PD studies on UTI and its treatment, the relative importance of antimicrobial concentrations of broad-spectrum antibiotics in plasma or urine remains controversial^{46,47}. Urinary concentrations of antimicrobial agents are often 100-150 fold higher than serum concentrations over a dosing interval, and human data indicates that urine concentrations are more closely associated with clinical outcome than serum concentrations for lower UTI^{53,54}. For the treatment of APN, however, high serum and tissue concentrations of the antimicrobial agent are required⁴⁷. The PK/PD targets for optimal antimicrobial activity in patients with APN have not been studied specifically; nevertheless, experimental data derived from a model of ascending UTI in mice suggested that, in kidney infections, the plasma PK/PD indices of efficacy characteristic of the different antibiotic classes correlate with antibacterial activity in kidney tissue and urine⁴⁶. At least in the case of beta-lactams, it is clear that dosages that achieve effective concentrations in urine but not plasma are unable to reduce the bacterial burden in the kidneys⁵⁵.

In order to optimize dosing strategies in acute uncomplicated AC and APN, specific PK/PD indices for UTIs can be calculated from mean serum and peak urine concentrations and the AUC (tables 1 and 2). To take an example, for uncomplicated AC, fosfomycin trometamol (FT) (an antibiotic with concentration-dependent activity and a long post-antibiotic effect)⁵⁶ reaches urinary concentrations of >500 mg/L for at least 18-20 h after a 3 g dose. The C_{max}/MIC values (table 1) are at least ten times higher than the standard values that predict efficacy in concentration-dependent antibiotics (138 vs. 10 for aminoglycosides). Inconsistencies

between susceptibility and the predicted efficacy of antibiotics have already been reported. Indeed, CLSI and EUCAST-defined breakpoints for Gram-negative bacilli may overestimate susceptibility, two to fourfold higher than those estimated with PK/PD simulations⁵⁷. Table 2 shows the MIC values at which the PTA is $\geq 90\%$ for six antimicrobial agents used in the treatment of APN⁵⁸. In sequential therapy, the dose and subsequent exposure to the active drug is considerably lower with oral antibiotics than with the previous parenteral treatment, with the available daily dose reduced by up to 80%. The commonly used oral dosing regimens for AMC (500/125 mg q8h, 875/125 mg q8h) and CXM (500 mg q8h) are expected to provide efficacy for organisms with MICs of up to 2 mg/L (for $f_T > \text{MIC} \geq 40\%$) or 0.75 mg/L (for $f_T > \text{MIC} \geq 65\%$), respectively^{59,60}. However, for pathogens with higher MIC values (such as MIC of AMC of 4 or 8 mg/L), the adequacy of the proposed dosing regimen when switching to an oral formulation would be unacceptable. Although there are no specific articles for patients with APN that report higher failure rates compared with those infected with very susceptible strains, we have observed failure in cases like this when AMC was switched from the intravenous to the oral route.

RECOMMENDATIONS

1. Human data indicates that urinary concentrations are more closely associated with clinical outcomes than serum concentrations for lower UTI. For the treatment of pyelonephritis, however, high serum concentrations of the antimicrobial agent are required (A-III).
2. With beta-lactams, the efficacy of sequential therapy may decrease due to the significant reduction in exposure to the active drug when switching to oral formulations for pathogens with higher MIC values (C-III).

Asymptomatic bacteriuria

Is pyuria useful for diagnosing asymptomatic bacteriuria? Are urine rapid tests recommended for screening of asymptomatic bacteriuria?

AB is defined in section 2.3. Pyuria (the presence of ≥ 10 leukocytes/mm³ in uncentrifuged urine) can be determined in patients with non-infectious inflammatory processes, and in patients with AB, it changes over time. Its presence however does not correlate with a higher incidence of sUTI, so that pyuria cannot be considered an adequate criterion for establishing a diagnosis of AB, and the presence or absence of pyuria does not help distinguish between symptomatic and asymptomatic UTI³.

Detection of urine leucocytes or nitrites by urine test stripes for screening of asymptomatic bacteriuria has a low sensitivity and specificity⁶¹, and are not recommended for the detection of AB.

RECOMMENDATION

1. Pyuria cannot be considered as an adequate criterion for the diagnosis of AB nor for indication for treatment in a patient with AB (A-II). Urine test stripes are not recommended for the detection of AB (A-II).

Asymptomatic bacteriuria in at-risk populations

Pregnant women

The incidence of AB in pregnant women is from 2–10%⁶² and has clinical impact, so that it is critical to diagnose and treat it. There is a well-established association between AB and APN during pregnancy. APN increases the incidence of other maternal complications, such as sepsis, acute respiratory failure, acute renal failure and anaemia^{63,64}, and several studies have associated it with a greater risk of foetal complications, such as low birth weight infants and preterm labour^{64–66}.

Antibiotic treatment is effective in eradicating AB. A meta-analysis involving 14 randomized or quasi-randomized studies associated it with a significant 77% reduction in the risk of developing APN (OR, 0.23; 95%CI, 0.13-0.41)⁶⁷. Table 3 describes the results of several studies on the treatment of AB during pregnancy^{68–81}.

In a recent study involving 4,283 pregnant women, only 248 (5.8%) had AB, 40 of whom were treated with NIT (100 mg/12 h for 5 days), 45 with placebo (every 12 h for 5 days) and 163 were left untreated. A significant association between AB and the risk of developing APN was confirmed, although not in relation to treatment, since the risk of APN did not differ between treated and untreated AB patients⁸¹. The methodological limitations of the study make it difficult to modify the current recommendations and encourage new studies to be performed⁸². Treating AB also reduces the risk of hospitalisation due to APN, from 3–4% before systematic screening was implemented, to 1.4% in the study performed by Hill *et al* in 2005⁶³.

The relationship between AB and the risk of preterm labour and low birth weight infants is less clear^{66,78,81,83}. With regard to the risk of preterm labour in pregnant women treated for AB, two studies with some limitations proved that the risk was lower after treatment^{78,83}. Two other meta-analyses^{67,84} also noted that treatment resulted in less risk. However, another study⁸¹ did not identify any differences with respect to the risk of preterm labour or low birth weight infants.

The ideal moment for systematic screening for AB has not yet been clearly determined. It seems reasonable to carry out systematic screening⁸⁵ between the 12th and 16th week of pregnancy, since there is a higher incidence of AB during this period⁸⁶. Implementation of a systematic screening program reduced the incidence of APN by 67%⁸⁷.

There is a high recurrence rate for AB in adequately treated pregnant women (up to 30%), and the Spanish Society of Gynaecology and Obstetrics (SEGO) recommends performing monthly follow-up urine cultures until⁸⁵.

RECOMMENDATIONS

1. Systematic screening and treatment of AB is recommended for pregnant women (A-I) in order to reduce the risk of pyelonephritis (A-I), preterm labour and low birth weight infants (B-II). An initial urine culture between the 12th and 16th week of pregnancy is recommended (A-I).
2. A follow-up urine culture is recommended in order to verify that the bacteriuria has been eradicated (A-III). Subsequent monthly urine cultures until delivery are recommended (C-III).

Patients who must undergo urological procedures

For patients with AB who are scheduled to undergo urological procedures, mucosal bleeding is a critical criterion for identifying high- and low-risk patients, and consequently considering initiating prophylactic antibiotic treatment due to the risk of onset of bacteremia and sepsis⁸⁸.

High-risk urological procedures. For transurethral resections of the prostate (TURP), patients with AB prior to undergoing the procedure have a 60 per cent risk of developing bacteremia and a six to ten per cent risk of developing sepsis if they do not receive antibiotic prophylaxis⁸⁸. Ad hoc⁸⁹ and retrospective randomized studies^{90–93} proved that antibiotic treatment was effective in preventing bacteremia and sepsis. Antibiotic prophylaxis should be administered prior to performing a transrectal prostate biopsy, regardless of whether or not bacteriuria is present, given that in a recent meta-analysis⁹⁴, prophylaxis was seen to reduce the risk of bacteriuria, bacteremia, sUTI and hospitalisation.

After endourological or percutaneous procedures to treat ureterolithiasis, the presence of bacteriuria before the procedure constitutes a risk factor for bacteremia⁹⁵. There is very little significant information about other urological procedures associated with a high probability of mucous bleeding (high risk), since antibiotic prophylaxis is common in clinical practice⁹⁶. As for those cases where the patient requires the placement of a urethral catheter, some authors recommend prolonging treatment until it is removed, provided that it is temporary^{88,89,97}.

Low-risk urological procedures. According to a 2008 meta-analysis and European, American and SEGO guidelines, systematic screening and treatment of AB is not recommended. Although prophylaxis reduces the incidence of AB, it does not reduce that of postoperative sUTI^{3,98,99}.

In patients who underwent cystoscopy without the use of intravesical instillations or antibiotic prophylaxis, only 3.5% with bacteriuria and 1% without it ($p = 0.08$) developed sUTI¹⁰⁰. No infectious complications were recorded in a study involving urodynamic procedures, although AB persisted in a third of the patients examined and 3.6% of women with no previous history of AB acquired infection¹⁰¹. The risk of infection, including symptomatic bacteremia, during replacement of long-term urinary catheters is very low, so that antibiotic prophylaxis is not recommended in this situation either^{102,103}.

RECOMMENDATIONS

1. Systematic screening for and treatment of AB is recommended prior to performing a TURP of the prostate (A-I) or any other high-risk urological procedure (A-II).
2. Screening and prophylaxis for AB is not recommended for patients scheduled to undergo low-risk urological procedures (A-I).
3. Antibiotic prophylaxis should be initiated immediately before performing the procedure (A-II) and may be prolonged only in patients with a short-term urethral catheter, until removal (C-III).

Premenopausal, non-pregnant women

The prevalence of AB in this population is from 3-5%¹⁰⁴. Although UTI is more common in young patients with bacteriuria, treatment is not recommended for these cases, since studies showed absence of bacteriuria at the 1-year follow-up in 55% of treated and 36% of untreated women. The incidence of UTI was 36.7% and 35.5%, respectively. Furthermore, of the 88 women who did not have bacteriuria, 5% developed AB and 7% sUTI¹⁰⁵.

Treatment of AB is not recommended for women who suffer rUTI. In a randomized study involving 673 female patients, 26.9% of the treated group vs. 85.3% of the untreated group achieved microbiological eradication. In addition, the percentage of sUTI was significantly higher in the treated group¹⁰⁶. Increased rates of resistance to AMC, COT and FQs

were also observed in the treated group at the three-year follow-up¹⁰⁷. In another study, no association was detected between AB and higher mortality or impaired renal function at the 24-year follow-up¹⁰⁸.

RECOMMENDATIONS

1. Systematic screening for AB is not recommended for non-pregnant women under the age of 60 (E-I).
2. Treatment of AB in non-pregnant women under the age of 60 increases the risk of sUTI and rates of antibiotic resistance (B-I).

Diabetic women

In patients with diabetes mellitus, the incidence of AB is 3% in men and between 5 and 25% in women¹⁰⁹. AB correlates with duration and complications of the disease, but not with recent metabolic control¹¹⁰.

A randomized study revealed that antibiotic treatment of AB with COT or CIP increased microbiological eradication after 4 weeks; nevertheless, no differences in the incidence of sUTI or rate of hospitalisation for sUTI were reported. Furthermore, a greater number of adverse events were recorded in the treated group¹¹¹. Treatment of AB is also ineffective in terms of long-term microbiological eradication¹¹², with an 80% relapse rate after pharmacological treatment is discontinued¹¹³.

RECOMMENDATION

1. Systematic screening for and treatment of AB is not recommended for non-pregnant diabetic women (E-I).

Patients with urinary catheters

Short-term urinary catheter (<30 days). AB is common among patients with urinary catheters and is associated with a very low risk of severe infectious complications¹¹⁴. Although treating AB reduces its incidence, it does not reduce the prevalence of sUTI or severe complications, even in intensive care units (ICU)¹¹⁵, and it does increase colonization with resistant microorganisms³.

The AB episode tends to resolve spontaneously after catheter removal, especially in younger patients compared to elderly ones (74% vs. 4%). Treatment was only observed to reduce the incidence of sUTI in women when AB persisted 48 hours after removal of a short-term catheter¹¹⁶.

Long-term urinary catheter (>30 days). For those who wear permanent urinary catheters and suffer an AB episode, appropriate consecutive antibiotic treatment vs. no treatment eradicates bacteriuria, albeit with immediate recurrence of the episode. In such cases, treatment does not reduce the number of infectious febrile episodes or improve the patient's clinical condition and is associated, in the case of recurrent episodes, with the replacement of the original bacteria by antibiotic-resistant strains^{3,117–119}. Treatment of AB, therefore, is not recommended for patients with permanent urinary catheters. Asymptomatic candiduria is frequent and also does not require treatment.

Prophylaxis is not systematically recommended either during the removal or replacement of a catheter in order to reduce the risk of UTI¹. Although there is some risk of

bacteremia associated with mobilization of the catheter, the episode would, in most cases, be transient and asymptomatic^{102,103,120}. Based on our own experience, antibiotic treatment may be advisable during traumatic replacements associated with haematuria, since there have been some reports of episodes of symptomatic bacteremia.

RECOMMENDATIONS

1. Systematic screening for and treatment of AB is not recommended for patients with short-term (E-II) or long-term urinary catheters (E-I).
2. Treatment of AB in women is recommended only if AB persists 48 hours after removal of the catheter (B-I).
3. Systemic antibiotic prophylaxis is not recommended during catheter replacement, since the risk of onset of symptomatic bacteremia is low (E-II); nonetheless, it may be recommended in cases of traumatic replacement associated with haematuria (C-III).

Elderly persons residing in the community

The incidence of AB increases with age and is estimated to be between 10.8% and 16% in women and 3.6% and 19% in men over the age of 70¹²¹. In such patients, treating AB with antibiotics achieves greater control of bacteriuria at the six-month follow-up, but does not reduce the frequency of sUTI^{122,123}. In randomized studies, treating AB did not reduce patient mortality either¹²⁴.

RECOMMENDATION

1. Systematic screening and/or treatment of AB is not recommended for elderly patients living in the community (E-II).

Elderly institutionalised subjects

There is a higher incidence of AB in elderly institutionalised patients, estimated at between 25% and 50% in women and 15% and 40% in men¹²¹. Although antibiotic treatment in elderly institutionalised patients with AB is associated with better initial microbiological control, this situation is transitory, and only 6% of treated patients continued without bacteriuria or displayed fewer sUTIs secondary to treatment after 24 months¹²⁵. No associated benefits have been identified in terms of morbimortality. Moreover, the incidence of reinfection, adverse events or the isolation of resistant microorganisms during recurrent episodes is higher in the treated group¹²⁶.

RECOMMENDATION

1. Systematic screening and/or treatment of AB is not recommended for institutionalised elderly patients (E-I).

Patients about to undergo orthopaedic surgery

The incidence of preoperative AB prior to arthroplasty procedures is variable. However, the issue of whether or not it is worthwhile diagnosing and treating it in order to reduce the risk of surgical site infection is still a contentious one. In one study involving 510 cases planned for

joint replacement surgery, only 25 patients (5%) exhibited signs of UTI and there were no negative effects on the joint prosthesis¹²⁷. In another study, preoperative AB was not linked to prosthetic joint infection (PJI)¹²⁸; nonetheless, all patients included in both studies had received prophylactic treatment with CXM. In two further studies, preoperative treatment of AB did not reduce the incidence of PJI and the microbiological isolates obtained were different from the preoperative urine cultures^{129,130}.

In patients scheduled to undergo complex spinal fusion surgery, the evidence supporting the benefits of detecting and treating episodes of AB is weak. In one meta-analysis, despite the wide variety of source studies, AB was not considered to be a risk factor for infection after spinal surgery¹³¹. In a study with two consecutive cohorts, cohort A, where the presence of preoperative AB was not investigated, and cohort B, where preoperative AB was screened and treated in patients at risk of developing UTI (neurogenic bladder, urinary incontinence, indwelling catheter), rates of surgical wound infection among untreated and treated patients were 9.3% and 6.7% respectively ($p > 0.1$), and there was a significant decrease in the incidence of gram-negative infections (68.2% vs. 33.4%; $p < 0.04$)¹³².

RECOMMENDATIONS

1. Systematic diagnosis or treatment of AB is not recommended for patients scheduled to undergo total hip or knee arthroplasty (A-I).
2. Screening and treatment of AB prior to performing instrumental spinal surgery is recommended for patients with urinary catheters, neurogenic bladders or urinary incontinence in order to reduce the risk of gram-negative surgical site infections (B-II).

Patients with spinal cord injury

The incidence of AB in patients with spinal cord injury is 50% among patients undergoing sphincterectomy or intermittent catheterisation, and 100% in patients with permanent or suprapubic urethral catheters³, and the risk of sUTI is high (2.5 episodes/patient/year) due to the difficulty of emptying neurogenic bladders^{133–136}.

Treatment for AB did not reduce the incidence of sUTI and AB episodes tended to recur soon after antibiotic treatment and were associated with increased risk of selection of resistant microorganisms^{137–140}.

RECOMMENDATION

1. Systematic screening and treatment of AB is not recommended for patients with spinal cord injury treated with intermittent urinary catheterisation (E-II).

Transplant recipients

In renal transplant recipients, UTI is the most common infection, particularly in the first year after the transplant procedure^{141–143}. AB is not considered a risk factor for sUTI¹⁴⁴. The recommendations for the need to diagnose and treat AB are both controversial and variable; hence, the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines refuse to make any recommendation¹⁴⁵, whereas the ISDA guidelines³, the American Society of Transplantation Infectious Diseases Community of Practice and others^{142,146–149} recommend diagnosis and treatment in the first 3-6 months after the transplant due to the increased risk of onset of sUTI during this period, and the association with underlying urological abnormalities. A prospective randomized study assessed the impact of AB on cases of kidney transplants with at least one-

year post-transplantation follow-up and noted that 21% (9/43) of treated patients vs. 31% (14/45) of untreated patients developed sUTI ($p > 0.05$)¹⁵⁰. Two recent ad hoc studies analysed the impact of AB one month after transplantation and identified only one sUTI episode among untreated patients and none in treated patients^{141,151}. On the basis of these studies, as well as Spanish guidelines for UTIs and solid organ transplants (SOT) and a recent review, the screening and treatment of AB in kidney transplant recipients is recommended only in the first month after transplantation^{110,143}.

Although systematic treatment of asymptomatic candiduria has been recommended for patients with kidney transplants¹⁵², the new 2016 Infectious Diseases Society of America (IDSA) guidelines recommend treatment only for high-risk patients, such as neutropenic patients and/or patients scheduled to undergo urological procedures. In carriers of urinary catheters, removal of the catheter should suffice¹⁵³. Screening and treatment of AB has not yet been assessed for cases of SOT other than kidney transplants³, and the guidelines for prevention of infections in hematopoietic stem cell transplants do not include recommendations for the screening and treatment of AB¹⁵⁴.

RECOMMENDATIONS

1. For kidney transplant patients, the screening and treatment of AB is only recommended in the first month after transplantation (B-III).
2. For cases of hematopoietic stem cell transplants and SOTs other than kidney transplants, no recommendations for the screening and treatment of AB can be made (C-III).
3. Systemic antifungal therapy for asymptomatic candiduria is not recommended for transplant patients, except for neutropenic patients or those scheduled to undergo urological procedures (D-III).

Orthotopic neobladder

AB is very common in this group of patients, with a prevalence of 57–81%¹⁵⁵. Nevertheless, antibiotic treatment does not eradicate bacteriuria¹⁵⁶, but favours the selection of resistant microorganisms, thus supporting the recommendation not to systematically screen for or treat AB¹⁵⁵.

RECOMMENDATION

1. Systematic screening and treatment of AB is not recommended in patients with an orthotopic neobladder (D-III).

How long does it take to treat an asymptomatic bacteriuria?

Once indications for treatment have been determined, it is essential to determine its duration. The optimal duration of treatment of AB in pregnant women has not yet been defined. Table 4 describes studies comparing use of a single one-day dose vs. 4- to 7-day courses of antibiotic treatment for AB in pregnant women^{157–170}. Although one-day and single-dose treatment regimens theoretically improve compliance and entail significant advantages, a meta-analysis published in 2015¹⁷¹ that compared one-day treatment regimens (including single doses) with standard 4- to 7-day treatments concluded that eradication of bacteriuria was significantly higher in patients who received a 4- to 7-day course of treatment with the same antibiotic

(OR, 1.72), and similar when a single dose of FT 3 g was compared with a 5-day course of CXM¹⁶⁸ or a 7-day course of AMC or NIT^{169,170}.

In patients with AB scheduled to undergo urological procedures associated with a high risk of mucous bleeding, a single-dose therapy before the procedure (with a second postoperative dose if placement of a urethral catheter was involved) was as effective in preventing postoperative infections as prolonged preoperative treatment that continued until a negative urine culture was achieved. For cases where the patient requires placement of a urethral catheter, some authors recommend prolonging treatment until it is removed, provided that it is temporary^{88,89,97}.

Although a meta-analysis of antibiotic prophylaxis use in transrectal prostate biopsy proved that there was an increased risk of bacteriuria with single-dose versus multiple-dose antibiotic treatment (RR: 1.98; 95%CI: 1.18-3.33), the authors concluded that there was insufficient data to guarantee that a 3-day course of treatment was better than a 1-day treatment, that a multiple-dose regimen was better than a single-dose, or that the risk was related to route of administration of the prophylactic treatment¹⁷².

RECOMMENDATIONS

For pregnant women with asymptomatic bacteriuria

1. Standard 4- to 7-day treatment regimens are better than short one-day treatments for eradicating bacteriuria (A-I). Only a single 3 g dose of FT offers similar results to the standard treatment regimen (A-I).

For patients scheduled to undergo high-risk urological procedures

1. The administration of a single-dose of an appropriate antibiotic is recommended immediately prior to the procedure (A-II).
2. Prolonging antibiotic treatment after these procedures is only recommended for patients with a short-term urethral catheter and until it has been removed (C-III).

Treatment for acute uncomplicated cystitis

What is the first-choice empiric antibiotic treatment recommended for acute uncomplicated cystitis?

Although there is considerable variation in susceptibility rates to antibiotics between countries, the rates of antimicrobial resistance associated with the antibiotics specifically employed against UTI (FOF, pivmecillinam and NIT), in both recurrent and non-recurrent UTI^{173,174}, are low in all countries of Europe. The latest European guidelines include the three antibiotics mentioned above as first-choice agents for therapy for uncomplicated AC in women^{1,173,174}. Pivmecillinam is not currently available in Spain.

Fosfomycin trometamol. FOF, a phosphonic antibiotic, acts by inhibiting cell wall synthesis and has broad-spectrum bactericidal activity against staphylococci, enterococci, *Haemophilus* spp and most gram-negative enteric bacteria, including 95.5% of extended-spectrum beta-lactamase (ESBL)-producing *E. coli*^{175,176}.

In Spain, there is an intravenous formulation of FOF, disodium fosfomycin, and oral formulations, either calcium or tromethamine salts (also known as trometamol). FT is administered solely for treatment of uncomplicated AC in a single 3 g dose. It is absorbed best when taken before food¹⁷⁵. It reaches high concentrations in the urine and maintains high levels for over 24 hours^{175,176}. A recent open-label study estimated that fosfomycin calcium

(1 g administered three times daily for 2 days) provides comparable efficacy to treatment with a single 3 g dose of FT¹⁷⁷.

Several clinical studies have compared the clinical and microbiologic efficacy of FT with other first-line antimicrobials used against uncomplicated AC. The clinical efficacy of one (3 g) dose of FT (91% cure) is comparable to that of NIT (93%), COT (93%) and FQs (90%) in uncomplicated AC (table 5)². The microbiological cure rate of FOF (80%) is lower than with comparable antibiotics, 82% versus 94%^{1,21}, although a recent meta-analysis of 27 trials found no difference in efficacy between FOF and other antibiotics for the treatment of cystitis, and also that FOF was associated with significantly fewer adverse reactions in pregnant women¹⁷⁸. Furthermore, a recent randomized single-blind study found that one 3 g dose of FT was as effective as CIP at 500 mg twice a day for 5 days for the treatment of uncomplicated AC, as shown in table 6¹⁷⁹.

FOF is also useful for the treatment of MDR organisms. Several *in vitro* studies have demonstrated that FOF is active against vancomycin-resistant enterococci, methicillin-resistant *Streptococcus aureus*, and ESBL-producing gram-negative rods^{1,175,176,180}. Two studies evaluated oral FT treatment for ESBL-producing *E. coli*-related lower urinary tract infection, either in the form of a single 3 g dose or once every other night for three nights. Treatment with FOF was associated with clinical cure in 75 out of 80 (93.8%) patients included in these two studies¹⁸⁰. Observational studies also showed that FT can be effective in the treatment of UTI due to *K. pneumoniae* carbapenemase-producing Enterobacteriaceae as a 3 g dose repeated every 48 to 72 hours¹⁷⁵.

Finally, FOF appears to have minimal propensity for collateral damage. This assumption is supported by the high rate of *E. coli* susceptibility in regions where FOF is frequently used for uncomplicated AC in women¹.

Nitrofurantoin. NIT, a synthetic nitrofurantoin, was initially introduced in microcrystalline form. In 1967, a macrocrystalline form with improved gastrointestinal tolerance became available^{175,181}. Nowadays, there are two basic presentations of NIT: the macrocrystalline form and as a mixture of microcrystalline and macrocrystalline forms (25 mg macrocrystals plus 75 mg monohydrate form)^{175,181} blended in a patented dual delivery system, known in the USA as nitrofurantoin monohydrate/macrocrystals¹⁸². For UTI therapy, 50–100 mg of macrocrystalline nitrofurantoin is taken orally four times a day¹⁷⁵. The dose for the mixed microcrystalline and macrocrystalline formulation is 100 mg twice daily^{175,181}. The latter presentation is not commercially available in Spain.

NIT is active against more than 90% of *E. coli* strains causing UTI^{175,181}. Resistance to NIT is uncommon, probably because of the multiple sites of action of the drug. However, *Proteus*, *Serratia* and *Pseudomonas* have natural resistance to NIT¹⁷⁵. Enterococci, including those that are vancomycin-resistant, are susceptible to NIT. *S. aureus* and *S. saprophyticus* are usually susceptible¹⁷⁵. Although it has been suggested that NIT could also be an option for treating AC produced by ESBL-producing bacteria¹⁸⁰, a recent study showed low clinical (69%) and microbiological success rates (68%)¹⁸³.

Absorption is improved when NIT is taken with food¹⁷⁵. Serum concentrations are low or undetectable with standard oral doses, as are concentrations in prostatic secretions¹⁷⁵. The antibiotic is eliminated predominantly through the urine, where the drug concentration easily exceeds the MIC for susceptible organisms. NIT should not be administered to patients with creatinine clearance <60 mL/min¹⁷⁵. NIT has been used safely in pregnant women and children.

The established duration of therapy for NIT is 5-7 days¹⁸⁴. Clinical efficacy studies show that there is an overall equivalence between NIT administered for 5 to 7 days and COT, CIP and single-dose FT, with a clinical cure rate for NIT of between 79% and 95%, and a microbiological cure rate of between 74% and 92%^{1,175,181}.

NIT is now considered a first-line therapeutic agent for acute uncomplicated AC because of the efficacy of the 5-day course of treatment and the small risk of collateral damage to normal human flora¹. NIT should not be used to treat APN^{1,2,175,181}.

Fluoroquinolones. Several studies have demonstrated the efficacy of FQs in the treatment of UTI. Overall clinical and bacterial efficacy rates in studies are consistently high, although occasionally they have been <90% (table 5)¹. A recent meta-analysis showed that FQs are the most effective therapy compared with other antimicrobials¹⁸⁵. According to a Cochrane analysis, all FQs suitable for UTI therapy show the same effectiveness for this indication, although tolerability may vary¹⁸⁶. Table 7 summarizes the dosages for different FQs. Single-dose FQ therapy may be an option for uncomplicated AC, but has lower effectiveness than 3-day regimens¹.

The main concern with respect to FQ use in AC is the appearance of resistance, not only among uropathogens, but also other organisms, including MRSA, that cause more serious and difficult-to-treat infections at other sites¹. The IDSA guidelines therefore advise limiting the use of FQs to episodes of uncomplicated AC for which other UTI antimicrobials are unsuitable¹.

β -Lactams. In the IDSA guidelines, pivmecillinam was proposed as a first-line drug for empiric treatment of uncomplicated AC¹, although this drug is not licensed in Spain. Ampicillin and amoxicillin can no longer be recommended as empiric treatment, given the very high prevalence of antimicrobial resistance^{1,2,187}.

The most commonly used β -lactams for the treatment of lower UTI have been AMC and oral cephalosporins. Second-generation oral cephalosporins (CXM, cefaclor) show improved activity against *E. coli* compared to first-generation cephalosporins, but less activity than those of the third-generation (cefditoren pivoxil, cefixime, cefpodoxime proxetil and ceftibuten)¹⁸⁷. In the ARES study, the overall resistance patterns of *E. coli* isolates and all uropathogens to CXM were very similar to those for AMC⁶. Table 7 shows dosages for the most commonly used cephalosporins in our country for treatment of UTI. Most studies demonstrate that β -lactams (in 3-7 day regimens) generally have worse cure rates than FQs^{1,21,185,187}. A recently published randomized controlled trial on cefpodoxime showed that it was inferior to CIP¹⁸⁸. In addition, a recent meta-analysis showed that the efficacy of AMC was low compared to other antibiotics¹⁸⁵. Possible explanations for this inferiority are that β -lactam use is associated with a lower rate of eradication of vaginal uropathogens and persistence of the reservoir of infection^{1,21}, or that it has low intracellular penetration, which could make intracellular uropathogens difficult to eradicate¹⁸⁹. AMC may also be useful for treating patients with cystitis due to susceptible ESBL-producing Enterobacteriaceae¹⁸⁰. In clinical practice, because it is a broad-spectrum drug, it is associated with increased risk of vaginal candidiasis⁶.

The use of broad-spectrum cephalosporins has been associated with collateral damage, the most disturbing being ESBL resistance among gram-negative bacteria¹. As a result, experts advise avoiding β -lactams for empiric therapy of uncomplicated AC, unless none of the recommended agents are appropriate.

Co-trimoxazole. (Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days) is a highly effective antimicrobial for the treatment of AC, with clinical and microbiological cure

rates ranging between 86% and 100% and between 85% and 100%, respectively (table 5)¹. It involves less collateral damage than broad-spectrum cephalosporins or FQs¹ and is therefore recommended as a first-line agent in the IDSA guidelines when the rate of resistance is expected to be <20%. Previous data has shown that TMP (100 mg twice daily for 3 days) was equivalent to it in combination with sulfamethoxazole¹.

In Spain, however, the reported resistance patterns of *E. coli* to COT have varied from 27% to 34%^{6,173,190} and it should not be used as empiric treatment. Nevertheless, COT is an excellent antimicrobial in cases known to be caused by susceptible strains of uropathogenic bacteria.

In conclusion, the choice of agent should be individualized on the basis of the patient's allergy and compliance history, prevalence of local community resistance, availability, cost, and ecological impact. If the first-line antimicrobial agents (FT or NIT) are not a good choice on the basis of one or more of these factors, FQs or β -lactams are reasonable alternatives, although it is preferable to minimize their use because of concerns about ecologically adverse effects (and efficacy in the case of β -lactams).

Regarding the duration of AC treatment, the effectiveness of short therapy has been only adequately studied in healthy (young and elderly) women with uncomplicated non-recurrent cystitis with short symptom duration. For patients with symptoms longer than 7 days, recent UTI (<1 month), with diabetes, renal insufficiency or immunosuppression or with a vaginal diaphragm, a longer course of antibiotic therapy (at least 7 days) is recommended. In men, the efficacy of a short course therapy has not been evaluated, and treatment has been traditionally administered for 7-14 days¹⁹¹. If FT is used, a 3 g dose should be administered on day one and four.

RECOMMENDATIONS

1. Due to minimal resistance and propensity for collateral damage, fosfomycin-trometamol (3 g in a single dose) and nitrofurantoin (for 5-7 days) are considered the first-choice drugs for therapy of uncomplicated cystitis (A-I).
2. Fluoroquinolones (ciprofloxacin, levofloxacin and norfloxacin) are highly efficacious in 3-day regimens (A-I), but should be considered as alternative antimicrobials because of their high propensity for collateral damage (B-III).
3. β -lactam agents, including amoxicillin-clavulanate, cefuroxime, ceftibuten, for 5 days, and cefixime for 3 days regimens, are appropriate choices for therapy when other recommended agents cannot be used (B-I). β -lactams generally have inferior efficacy and more adverse effects when compared with other UTI antimicrobials (B-I). Ampicillin and amoxicillin should not be used for the empiric treatment of uncomplicated cystitis, given the high incidence of antimicrobial resistance to these agents (E-I).
4. Co-trimoxazole is not recommended for empiric treatment in Spain, because the resistance rate in *E. coli* is greater than 20% (E-I). If the infectious organism is susceptible to co-trimoxazole, this agent is very effective therapy (A-I).
5. In men, and in women with symptoms longer than 7 days, recent UTI, diabetes, renal insufficiency, immunosuppression or with a vaginal diaphragm a longer course of antibiotic therapy (at least 7 days) is recommended (C-III).

Community-acquired acute pyelonephritis

In these guidelines, “complicated APN” refers to any episode occurring in patients with any conditions predisposing to poor outcomes, even if they receive appropriate antibiotics. These include: a) men, children, pregnant women and individuals aged ≥ 65 ; b) women with functional or anatomical urinary tract abnormalities that cause obstruction or voiding disorders, any sort of ureteral derivation or foreign body (including indwelling bladder catheters), polycystic kidney disease, single kidney, recent (within 1 month) instrumentation or urinary tract surgery, diabetes mellitus, renal insufficiency or transplantation, other immunosuppressed states or underlying diseases (liver cirrhosis, active malignancy, congestive heart failure), and c) severe sepsis.

What are the criteria for hospital admission in adult patients?

Any of the above conditions in association with complicated APN is a criterion for hospitalization. At the same time, circumstances that increase the risk of MDR microorganisms are also relevant for making decisions about the place of care. These include patients with the following conditions defining “healthcare-associated urinary tract infections” (HCA-UTI): a) receiving intravenous therapy, wound care or specialized nursing care at home in the 30 days prior to the episode; b) attending a hemodialysis ward or receiving intravenous chemotherapy in the 30 days before the episode; c) hospitalization in an acute-care hospital for 2 days or more in the 90 days before current hospitalization; d) residence in a nursing home or long-term care facility (LTCF); e) undergoing an invasive urinary procedure in the 30 days before the episode or having a long-term indwelling urethral catheter.

At least two well-designed controlled prospective trials^{15,192} and a small randomized trial¹⁹³ have demonstrated that women under 60 with APN who tolerate oral intake, do not present severe sepsis, have no history of functional or anatomical abnormalities of the urinary tract or significant comorbidities and do have access to medical follow-up, can be safely managed as outpatients with appropriate oral antibiotics. Multiple studies^{194–202} have consistently shown that women with mainly uncomplicated APN and pregnant women with otherwise uncomplicated non-bacteremic UTI can be safely discharged and treated with an appropriate oral antibiotic after an observation period of up to 24 h and 1-2 doses of parenteral antibiotics.

In pregnant women, two randomized trials compared outpatient and inpatient approaches^{200,201} and found no difference in success between oral and intravenous regimens²⁰³. Some authors prefer hospital admission because pregnant women remain at an increased risk of respiratory failure ($\approx 7\%$), acute renal dysfunction or preterm labour⁶³.

Finally, there are observational studies that indicate that patients with APN can be managed in a hospital-based home unit when intravenous antibiotics are required or daily control of an underlying disease is considered necessary²⁰⁴.

Although advanced age is not commonly mentioned as a criterion for complicated APN¹⁸, several retrospective studies have found that it is an independent predictor of mortality^{205,206}. There is almost no evidence that male gender is an independent predictor of poor outcome, although it may still be justified to consider APN in men as complicated because of its higher association with urological abnormalities. There has also been some controversy concerning diabetics when there is no renal insufficiency or functional or anatomical abnormalities. Nonetheless, the association of diabetes with some severe complications and the frequent requirement for better metabolic control justifies retaining diabetes in the complicated category. There is little information regarding the prognostic role

of other underlying diseases, although immunosuppression, liver cirrhosis, malignancy, congestive heart failure and having an ultimately or finally fatal underlying disease have all been associated with poor outcomes in observational studies^{205,207,208}. In several retrospective studies^{206,209}, leukocytosis $\geq 15,000$ -20,000/ μ L and serum C-reactive protein level of ≥ 15 -20 mg/dL were also independent predictors of early clinical failure.

Lastly, community-onset HCA-UTI is associated with increased rates of MDR in *E. coli*, as well as a higher incidence of non-*E. coli* microorganisms, inappropriate empiric therapy and worse outcome^{210,211}, so that these patients may justify a particular approach, regardless of whether the infection is considered as complicated on other grounds. In addition, for patients who do not fulfill the HCA-definition, the presence of at least two specific risk factors from recent receipt of FQs or cephalosporins, recent hospitalization, transfer from another healthcare facility (including long-term care facilities), recent urinary catheterization, older age (>70 years), and a Charlson score higher than 3, may still place the patient at sufficient risk of ESBL-producing gram-negative enteric bacilli as to consider specific parenteral treatment until microbiological data are available²¹². Recent travel to highly endemic areas or previous infection/colonization with ESBL-producing Enterobacteriaceae should also be taken into account²¹².

RECOMMENDATIONS

1. Women with uncomplicated APN and mild to moderate symptoms (fever < 39 °C, no severe flank pain, no vomiting) can be treated as outpatients (A-II).
2. Women with uncomplicated APN but with social, mental or physical disabilities that might hinder adherence to a prescribed therapeutic regimen should be admitted to hospital (C-III).
3. Women with uncomplicated APN and severe symptoms (fever ≥ 39 °C, severe flank pain, vomiting) should be referred to an emergency room for evaluation, parenteral antibiotics and supportive measures (A-II). If, after 24 hours, there is improvement and good oral tolerance, the patient may be sent home with oral antibiotics (A-II).
4. Patients with complicated APN or healthcare-associated APN and those with risk factors for MDR Enterobacteriaceae should be admitted to hospital (A-II).
5. Pregnant women with otherwise uncomplicated APN and non-severe symptoms may be considered for treatment as outpatients if appropriate follow-up is assured (B-I). A normal abdominal ultrasonography is recommended before discharge (C-III).
6. Selected APN patients with no severe sepsis, no obstructive uropathy (as recorded by ultrasonography), no altered mental status, no metabolic abnormalities and who have a responsible caregiver at home, may be managed in a hospital-based home care unit (B-III).

What are the main therapeutic options for pyelonephritis in the different clinical situations, and which are not recommended for empiric treatment because of the high rate of resistance in our setting?

Aminoglycosides, beta-lactams, COT, and FQs have all been successfully used to treat patients with APN in prospective controlled trials^{15,209,213-216}.

Since *E. coli* would be involved in at least 65% of either uncomplicated or complicated cases of APN^{32,207}, the resistance rates of these microorganisms are of primary concern. However, there is little recent specific data on this issue in our country (2006 or later) for different subsets of patients with APN^{6,7,190,207,210,211,217}. All these studies as well as recent

unpublished studies (tables 8 and 9) showed high rates of resistance to ampicillin (49%-66%), COT (21%-36%), CIP (15-30% in community-acquired infections), and AMC (14%-24%), regardless of gender or setting. In community-acquired uUTI, *E. coli* resistance to third-generation cephalosporins was consistently below 10%, although this rate exceeded 10% (10.2%-25%) in series that included febrile infections in men, complicated APN and healthcare-associated infections^{207,210,211,218}. The prevalence of resistance to gentamicin (GEN) needs to be clarified; resistance rates range from 3.4% to 11% in community-acquired isolates^{190,219} to as high as 18% in healthcare-associated isolates²¹¹. *E. coli* susceptibility to piperacillin-tazobactam (PIP-TAZ), ceftolozane-tazobactam, amikacin (AMK) and FOF is at least 95% in patients with community-acquired infections, and virtually 100% in the case of carbapenems. Up to 88% of ESBL-producing *E. coli* strains and about 40%-55% of ESBL-producing *K. pneumoniae* are non-resistant to PIP-TAZ (CMI ≤ 16 mg/L)²²⁰, and there is some evidence that PIP-TAZ is appropriate for treating susceptible bacteremic ESBL-producing *E. coli* strains when the source is the urinary or biliary tract²²¹. However, resistance to PIP-TAZ of up to 16% has been described for Enterobacteriaceae causing community-onset healthcare-associated bacteremic UTI²¹⁰. *P. aeruginosa* and *Enterococcus* spp are a concern only in patients with community-onset HCA-UTI and, even in this context, frequencies have varied between 4% and 14% for *P. aeruginosa* and between 5% and 11% for enterococci^{210,211}.

An analysis of randomized controlled trials of doripenem, imipenem and levofloxacin (LVX), found a 31.8% rate of resolution for cUTI in patients who received inappropriate antibiotics, which was similar to the 28.6% observed in patients with uncomplicated infections who also received inappropriate therapy. These figures should be compared with the overall 80% microbiological eradication in patients who received appropriate therapy²²². Although the presence of bacteremia does not seem to have clinical or prognostic significance in women with uncomplicated infections^{31,32,35}, it may still be associated with severe sepsis in patients with complicated APN²²³. Therefore, when selecting an appropriate antibiotic regimen for patients with APN, it is important to take into account the regular MIC breakpoints and serum PK/PD efficacy targets for the different antibiotic classes (table 2). The use of drugs such as NIT, which reach very low serum levels after regular oral dosages is discouraged²²⁴, and some antibiotics with poor renal clearance (like tigecycline) have been less effective than others that achieve high urinary concentrations^{225,226}.

There is essentially no clinical experience about the use of FOF for the treatment of APN. FT at the usual dose of 3 g can obtain fosfomycin concentrations in plasma that remain above the MIC for susceptible *E. coli* for at least 12 h, but not necessarily 24 h, and the gastrointestinal tolerance of a higher dose (i.e. 3 g/12-24 h) administered over several days, as well as the risk of selecting resistant mutants may be of concern^{227,228}. FOF sodium salt can be administered intravenously in sufficiently high doses (~24 g/d) to guarantee not only a time above the MIC of 100% for susceptible gram-negative bacilli, but also for it to have a chance of preventing selection of resistance in the kidneys.

The main concern about aminoglycosides continues to be toxicity, particularly renal injury, which makes them second-choice antibiotics²²⁹. There is no evidence that adding an aminoglycoside to a β -lactam improves survival, reduces therapeutic failure or prevents resistance^{230,231}, although in patients with infections caused by MDR microorganisms, combination therapy is associated with an increased rate of appropriate empiric therapy^{232,233}.

Management of patients with a history of hypersensitivity reactions to beta-lactams continues to be controversial. Two systematic reviews have found that there is a significantly increased risk of allergic reactions to first-generation cephalosporins and cefamandole among

penicillin-allergic patients, but not to CXM or third-generation compounds^{234,235}. Based on this and additional observational evidence, several authors have suggested that CXM and third-generation cephalosporins can be safely administered to patients allergic to penicillins²³⁶. There is general agreement about the absence of cross-reactivity between aztreonam and other beta-lactams, except in those who have developed hypersensitivity to ceftazidime^{237–239}. A systematic review of patients with a clinical history of Ig-E-mediated hypersensitivity to penicillins who were subsequently given a carbapenem estimated that the incidence of any type of hypersensitivity reaction was 4.3%, and of IgE-mediated reactions, 2.4%; true cross-sensitivity in those with a positive skin test for penicillin allergy was very low (0.3%)²⁴⁰.

Once antibiotic susceptibility patterns are known, antibiotic treatment should be adjusted, particularly when broad-spectrum antibiotics are used empirically. Because of its low ecological impact, COT is preferred to FQs or third-generation cephalosporins. Daily recommended dosage in APN is shown in table 10.

RECOMMENDATIONS

1. In our setting, ampicillin, amoxicillin, amoxicillin-clavulanic acid, co-trimoxazole, fluoroquinolones, nitrofurantoin and fosfomycin-tromethamine are not recommended for the empiric treatment of acute pyelonephritis (A-III).
2. Parenteral antibiotic treatment is recommended as initial therapy for patients requiring hospital admission (A-III).
3. In patients with uncomplicated community-acquired acute pyelonephritis with no specific risk factors for ESBL-producing Enterobacteriaceae, empiric therapy with cefuroxime or a third-generation cephalosporin is recommended (A-II). For allergic patients, the alternatives are an aminoglycoside (B-I), aztreonam (B-II) or fosfomycin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).
4. In community-acquired APN with specific risk factors for ESBL-producing Enterobacteriaceae (at least two risk factors without severe sepsis and one with it) or previous infection/colonization with ESBL, ertapenem is an acceptable option (C-II), although other carbapenems (B-II) or piperacillin-tazobactam (B-III) are alternatives. For patients with penicillin allergy, the alternatives are amikacin (B-I) or intravenous sodium fosfomycin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).
5. In healthcare-associated APN, an antipseudomonal carbapenem is recommended (A-III) with ceftolozane-tazobactam or piperacillin-tazobactam as alternatives (C-III). For patients with severe sepsis, the addition of amikacin should be considered in order to increase the chances of providing appropriate empiric therapy against gram-negative bacilli (B-II). For patients allergic to penicillin, alternative treatments are aztreonam, amikacin or intravenous sodium fosfomycin +/- amikacin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).
6. Anti-enterococcal coverage is recommended for patients with healthcare-related APN and severe sepsis or cardiac conditions at high risk of endocarditis (C-III).
7. When the antibiotic susceptibility pattern is known, treatment should preferably be adjusted to the drug with least ecological impact, such as co-trimoxazole (C-III).

What is the optimal duration of antibiotic therapy? Does it vary depending on the particular antibiotic administered?

Several randomized controlled trials have evaluated the efficacy of antimicrobial therapy of different durations in patients with APN. The patients included in the studies tended to be women with non-severe APN and fast clinical improvement. In a small comparative study in women with uncomplicated APN, a 2-week regimen of either oral ampicillin or COT was just as effective in terms of bacteriological eradication as a 6-week regimen with the same antibiotics¹⁹². Another small trial among women with uncomplicated APN treated for 48-72 hours with GEN or tobramycin, then with active oral antibiotics, found no clinical and microbiological differences between patients treated for 10 or 21 days²⁴¹. In another larger unpublished study²⁴² that compared a single dose of ceftriaxone, followed by 400 mg/d of cefixime for either 7 or 14 days in women with uncomplicated APN, the rates of clinical and microbiological failure were similar. Recently, a double-blind randomized trial that compared ceftolozane-tazobactam (1.5 g/8 h) and LVX (750 mg), both given intravenously for 7 days for the treatment of patients with cUTI and APN²⁴³, showed similar composite clinical and microbiological success rates. Five further trials involving quinolones demonstrated the following: 7 days of CIP performed better than 14 days of COT¹⁵; 7 days of either fleroxacin²⁴⁴ or CIP²⁴⁵ performed as well as 14 days with the same antibiotic, and 5 days of LVX at 750 mg/d was as efficacious as 10 days of CIP^{246,247}. The only other antibiotics that have been tried in a 5-day regimen are aminoglycosides. In two small studies, netilmicin was as efficacious as CIP or parenteral β -lactams^{219,248}. Clinical comparative trials published so far do not rule out the possibility that the optimal duration of antimicrobial therapy in patients with APN may depend on the particular class of antibiotic used. For uncomplicated APN, there is no reason to prolong LVX or CIP for more than 7 days, or third-generation cephalosporins (oral or parenteral) for more than 10 days. There are limited controlled studies of aminopenicillins such as AMC involving adults, although one randomized trial of children with APN showed good results in 10 days^{249,250}. For COT, there is no controlled data to support using it for less than 14 days, although expert experience suggests that 10 days is enough for women who improve rapidly. Limited efficacy and toxicity data makes it advisable not to administer aminoglycosides for longer than 5 days.

There are no good quality studies for patients with severe or focal APN, or who respond slowly to antibiotic therapy. In this situation, most authors recommend a longer duration of antibiotic therapy.

RECOMMENDATIONS

1. In patients with uncomplicated acute pyelonephritis due to susceptible gram-negative enteric bacilli, 5 to 7 days of levofloxacin or ciprofloxacin is recommended (A-I).
2. In the case of third-generation oral or parenteral cephalosporins, a 7 to 10-day course is recommended (A-I). For amoxicillin-clavulanic acid and co-trimoxazole a 10-day course is recommended (A-III). For aminoglycosides, no more than a 5-day course is recommended (A-II).
3. For patients with severe or focal APN or slow response to appropriate antibiotics, a longer duration of therapy may be required (C-III).

What are the main indications for performing urological studies?

In patients with APN, urological studies are primarily aimed at diagnosing obstructive complications or abscess formation, which may require specific additional therapeutic

manoeuvres, such as drainage or prolonged antibiotic treatment. A diagnosis of APN on its own does not make it a priority, although it may be of additional interest in cases with doubtful or equivocal clinical symptoms. Currently, ultrasound imaging is the standard screening technique for detecting obstruction and may also be used to guide intervention, but it is quite insensitive for detecting an intrarenal abscess. Computerized tomography (CT) is the gold standard for establishing cause of obstruction and the nature and extent of intrarenal and extrarenal lesions. Magnetic resonance (MR) may be considered when exposure to ionizing radiation (pregnancy) or iodinated contrast (renal insufficiency, allergy) is contraindicated, although gas and calculi may produce voids that are difficult to interpret^{251–253}.

At least 95% of patients with uncomplicated APN cease to be febrile within 3 days of appropriate antibiotic therapy and follow an uneventful course with virtually no mortality^{15,245,254}. In no more than 4% of such patients with an initial response to antibiotics would an ultrasound scan of the urinary tract reveal abnormalities that would eventually lead to a change of therapeutic approach^{255,256}. Complicated APN on the other hand is associated with severe sepsis in about 25% of cases, septic shock in around 12%, and has a crude mortality of 6%–7%²⁰⁷. When fever persists after 72 h of appropriate antibiotic treatment or it fulfils the definition of complicated APN, ultrasonography may uncover urological abnormalities that can affect treatment in 25%–45% of patients²⁵⁷. Two studies of hospitalized patients with APN found a high rate of intrarenal abscesses (23.5%–39.5%) when sensitive imaging studies (CT or MR) were systematically performed^{257,258}. Of note, patients were referred to the hospital after a mean of at least 3 days with symptoms and many were receiving antibiotics, which suggests that cases of initial clinical failure were overrepresented. In another study of hospitalized patients²⁵⁹, abscesses were discovered by computed tomography in 17.7% of patients and were associated with hypotension, diabetes mellitus, acute renal failure and leukocytosis of more than 20,000/ μ L.

RECOMMENDATIONS

1. Urological studies are only recommended for patients with uncomplicated APN who continue with fever after 3 days of appropriate antibiotic treatment (A-III), for APN that fulfils the definition of complicated infection in these guidelines (including severe sepsis) (A-III) or for recurrent APN (C-III).
2. Urological study should also be considered when the clinical diagnosis is doubtful, either to confirm it or to rule out other processes (C-III).

Catheter-associated urinary tract infection

In these guidelines, catheter-associated UTI refers to infections occurring in those with indwelling or intermittent urethral, suprapubic or condom catheterization, as well as infections that develop within 72 hours of device removal. Regarding duration of catheterization, an indwelling urethral catheter is considered to be short-term when it remains in place for less than 30 days, and long-term when it is present for 30 days or more^{4,260–267}.

Most infections in patients with indwelling urinary catheters are usually asymptomatic and diagnosed when a specific quantitative count of a microorganism is isolated from urine in the absence of clinical signs or symptoms associated with the urinary tract. This clinical situation has been defined as catheter-associated asymptomatic bacteriuria (CA-AB).

Symptomatic infection (CA-UTI) is diagnosed when there is bacteriuria associated with symptoms or signs referable to the urinary tract. In recent years, multiple institutions have published guidelines for the diagnosis and management of CA-AB and CA-UTI, which differ in their clinical and epidemiological orientation^{264–268}.

The rate of acquisition of bacteriuria is 3% to 7% per day for patients with indwelling catheters, so that the prevalence of bacteriuria reaches around 50% and 100% after 2 weeks and one month of catheterization, respectively^{260,263}. The incidence of bacteriuria associated with single and intermittent catheterization is significantly lower (~5% and ~50%, respectively)²⁶³.

What is the etiology of UTI in patients with urinary catheters?

Initial infection, following insertion of a short-term catheter, is usually caused by a single organism, most often *E. coli* (32–39%) or other Enterobacteriaceae. *Enterococcus* spp (16–17%), *P. aeruginosa* (16–18%) or *Candida* spp may also be isolated^{260–263,269}. Monomicrobial infection due to *E. coli* is also characteristic of patients with neurogenic bladders managed with intermittent catheterization^{260,261}.

In patients with long-term catheterization, the UTI is usually polymicrobial. In addition to the pathogens commonly isolated from patients with short-term catheters, other microorganisms, such as *P. aeruginosa*, Gram-positive bacteria and yeast are frequently found^{114,260–262,270}. Urease-producing bacteria such as *P. mirabilis*, *K. pneumoniae*, *M. morganii* or *P. stuartii*⁴ are also common in long-term CA-UTI and cause relapsing infections due to catheter blockage²⁶⁰. *C. albicans* is the most frequently isolated yeast, but other species such as *C. glabrata* and *C. tropicalis* may also appear^{260–263}. Enterococci are frequently isolated, but these infections are rarely symptomatic. *S. aureus*, coagulase-negative staphylococci and *S. agalactiae* are uncommon causes of CA-UTI; the isolation of methicillin-resistant *S. aureus* or vancomycin-resistant *E. faecium* is extremely rare in our setting²⁶¹. The etiology of community-acquired CA-UTI is similar to nosocomial UTI²⁶³.

Data from the ENVIN study (2005–2010)²⁷¹ showed increasing rates of ciprofloxacin-resistant *E. coli* and *P. aeruginosa* strains (37%) and of imipenem-resistant *P. aeruginosa* isolates (36%)²⁷². Bacteria causing CA-UTI are usually more resistant to antimicrobials due to frequent patient contact with the healthcare system and to the common use of antibiotic treatments for these infections^{261–263,272}.

RECOMMENDATIONS

1. In patients with short-term catheterization, UTI is usually monomicrobial and frequently caused by Enterobacteriaceae (B-II).
2. In patients with long-term catheterization, UTI is usually polymicrobial and frequently caused by antimicrobial-resistant bacteria (B-II).

What are the clinical and microbiological features for diagnosis of symptomatic CA-UTI?

Approximately 10–25% of patients with bacteriuria develop symptomatic UTI and between 1% and 5% develop bacteremia^{114,262}. CA-UTI is most frequent among women, diabetic and old patients, those with urinary tract obstruction or haematuria due to catheterization, or when *Serratia* spp is isolated from the urine^{261–263}. Bacteremia is an infrequent complication of

short-term catheterization and depends on the origin. While UTI causes 15-20% of nosocomial bloodstream infections, less than 5% of cases among ICU patients originate in the urinary tract^{260,262}. In LTCFs, CA-UTI is associated with more than 50% of episodes of fever and is the most frequent cause of bacteremia²⁶⁰.

The microbiological diagnosis of patients with CA-AB and CA-UTI is specified in section 2.3. A urine culture should be obtained before initiating therapy for patients with suspected CA-UTI. Urine specimens collected via a catheter are usually contaminated by biofilm bacteria, and more organisms and higher quantitative counts are isolated compared to bladder urine obtained after changing the catheter²⁷³. Thus, when the catheter has been in place for a prolonged period (>2 weeks), the catheter should be replaced and a urine specimen be collected for culture via the newly inserted catheter^{4,260,261}. Urine specimens should never be obtained from a urine collection bag. Blood cultures should also be drawn if the patient has fever or other clinical signs of sepsis.

The clinical features of CA-UTI are non-specific. CA-UTI is usually asymptomatic and the most common symptomatic presentation is fever without localizing urinary findings and no identifiable alternative source. Urinary tract symptoms such as dysuria, frequency, or urgency are less frequent, but may occur with infection appearing after catheter removal^{4,260,261}. There is little evidence in the literature about the clinical signs and symptoms of urinary infection in catheterized patients²⁶⁸. The usual localizing symptoms of lower UTI are useful for diagnosis of infection only in patients whose catheters have recently been removed.

The main risk factors associated with symptomatic infection are catheter obstruction or manipulation, complicated by haematuria, which usually precedes onset of fever or bacteremia²⁶⁰. Consensus criteria proposed for obtaining urine cultures and initiating empiric antimicrobial therapy for presumed CA-UTI in nursing home residents include fever, costovertebral angle tenderness, rigors, and new onset delirium, with no other obvious source^{274,275}. No study has demonstrated that odorous or cloudy urine is clinically significant in catheterized patients, and so these findings should not be used to distinguish CA-AB from CA-UTI^{4,260}.

The classic symptoms of UTI are usually absent in patients with spinal cord injuries and neurogenic bladders. Signs and symptoms suggestive of UTI in these patient groups include fever, costovertebral or pelvic pain, incontinence, increased spasticity, autonomic dysreflexia, lethargy, malaise, and sense of unease^{4,276,277}. Most of these symptoms and signs however have low sensitivity and specificity for diagnosing UTI or even identifying bacteriuria²⁷⁸. Finally, some patients may have typical signs of specific forms of UTI, such as urethritis, periurethral abscess, pyelonephritis, prostatitis and epididimitis^{260,262}.

RECOMMENDATIONS

1. If an indwelling catheter has been in place for >2 weeks, the catheter should be replaced before obtaining urine for culture (A-II).
2. Signs and symptoms compatible with CA-UTI include fever, rigors, altered mental state or malaise with no other identifiable cause, as well as focal signs in the urinary tract, such as flank or pelvic pain, costovertebral angle tenderness, and acute haematuria (A-III).
3. In catheterized patients, the presence of urinary symptoms is of limited value for differentiating CA-AB from CA-UTI (A-I). In patients, whose catheters have been removed, the presence of urinary symptoms is suggestive of symptomatic UTI (A-III).
4. In patients with spinal cord injuries, increased spasticity, autonomic dysreflexia, or a sense of unease are suggestive of CA-UTI (A-III).

5. In patients with indwelling catheters residing in LTCFs, the clinical criteria for obtaining urine cultures and initiating antimicrobial therapy include fever, costovertebral angle tenderness, rigors or new onset delirium with no other obvious source (A-II).

6. In catheterized patients, the presence or absence of odorous or cloudy urine should not be used to distinguish CA-AB from CA-UTI or as an indication for a urine culture or antimicrobial therapy (A-III).

Does the presence of pyuria indicate symptomatic UTI?

In catheterized patients, the presence of pyuria is a sensitive but non-specific finding for predicting CA-AB or CA-UTI. Indwelling catheters cause bladder irritation leading to inflammation and pyuria, even without bacteriuria. Significant pyuria (≥ 10 leukocytes/ μ l) accompanies bacteriuria in most patients with CA-UTI, and to a similar degree in CA-UTI and CA-AB, regardless of type of catheterization (indwelling or intermittent) or its duration (short-term or long-term)^{4,260,261}.

Pyuria is less frequent in patients infected with urease-producing bacteria²⁶¹. The absence of pyuria in a catheterized patient, however, should suggest a diagnosis other than CA-UTI^{4,260}.

RECOMMENDATION

1. In catheterized patients, pyuria is not diagnostic of CA-AB or CA-UTI (A-II). The absence of pyuria in a symptomatic patient suggests a diagnosis other than CA-UTI (A-III).

Is the Gram stain useful for guiding empiric antimicrobial treatment in CA-UTI?

The urine Gram stain test has the advantage of providing immediate microbiological information about the nature of the infecting bacteria or yeast and correlates well with the presence of significant bacteriuria. Sensitivity depends on the bacterial count, so that it is usually positive when it is $\geq 10^5$ CFU/mL²⁴. As a general recommendation, it can be useful in patients with APN and cases of invasive UTI with severe infection when information is urgently needed about the microorganisms involved^{24,262}. In catheterized patients, the urine Gram stain test is especially useful for guiding empiric therapy, since finding Gram-positive bacteria suggests the presence of enterococci, streptococci, or staphylococci, which is helpful for selecting an antimicrobial active against these microorganisms²⁶¹.

RECOMMENDATION

1. In catheterized patients, the urine Gram stain may be useful for guiding empiric antibiotic therapy in patients with severe UTI (B-III).

Should previous antibiotic use be considered for the selection of empiric therapy of CA-UTI?

Empiric antimicrobial treatment should provide adequate coverage against the most frequent microorganisms causing infection. Previous antimicrobial therapy received by the patient is associated with an increased risk of selection of resistant bacteria. To guide empiric therapy

of CA-UTI, it is essential to investigate the history of antibiotic use as well as previous colonization with, or infections caused by, MDR bacteria²⁶¹.

In recent years, an increasing prevalence of MDR *E. coli* and *K. pneumoniae* due to extended-spectrum beta-lactamases (ESBL) has been observed; these are no longer confined to the hospital setting, but appear at community level, and are especially common in LTCFs²¹². Many risk factors have been described for ESBL-producing bacteria. Two recent studies have developed predictive scores for the detection of community-acquired ESBL-producing Enterobacteriaceae^{279,280}. It is noteworthy that both studies identified urinary catheterization (in the previous month) and therapy with beta-lactams or FQs (in the previous three months) as two of the most important risk factors, along with comorbidity, previous hospital admission and transfer from a LTCF. Previous antimicrobial therapy should, therefore, be taken into account to guide empiric antimicrobial therapy of CA-UTI. In Spain, the increasing detection of MDR carbapenemase-producing Enterobacteriaceae and *P. aeruginosa* as a cause of nosocomial UTI has further complicated this worrisome epidemiological situation²⁸¹.

RECOMMENDATION

1. In catheterized patients with suspected UTI, recent use of beta-lactams or quinolones should be investigated in order to evaluate the risk for MDR bacteria (B-II).

What is the empiric antimicrobial therapy for patients with CA-UTI?

Empiric antimicrobial therapy for CA-UTI should consider the clinical situation of the patient, the site of infection and local resistance patterns of infecting organisms^{4,260–263,282}. Antimicrobial therapy is indicated for patients with symptomatic infection (pyelonephritis, prostatitis, epididymitis, bacteremia and so on) or clinical signs of sepsis²⁸². As a general rule, broad-spectrum antimicrobials active against Enterobacteriaceae, *P. aeruginosa* and *E. faecalis*²⁶⁴ should be used. Algorithms have been developed using clinical and microbiological factors (site and severity of infection, drug allergy, local patterns of resistance, urine Gram stain, etc.) for the selection of empiric therapy^{261,263}.

Critically ill patients with severe sepsis or hemodynamic instability should receive parenterally-administered broad-spectrum beta-lactam antibiotics active against MDR Enterobacteriaceae and *P. aeruginosa*, such as imipenem, meropenem or PIP-TAZ, due to the high rate of resistance to FQs in our setting^{264,282}. If the patient has septic shock or there is suspicion of beta-lactam resistance, combination therapy with an aminoglycoside such as AMK should be used pending the results of cultures^{261,263}.

Antimicrobial therapy for invasive infections due to MDR Enterobacteriaceae (ESBL and carbapenemase producers) was recently reviewed in the SEIMC guidelines²¹²; carbapenems are the drugs of choice for invasive infections caused by ESBL- and AmpC-producing Enterobacteriaceae, although PIP-TAZ may be considered a reasonable alternative for invasive UTIs caused by ESBL-producing *E. coli* due to increasing rates of resistance to carbapenems among Gram-negative bacteria and can be used as a carbapenem-sparing regimen²¹². PIP-TAZ is active in vitro against *E. faecalis*, most AmpC isolates and ESBL producers, as well as *P. aeruginosa*. Empiric coverage against Gram-positive bacteria such as *E. faecalis* and *S. aureus* should be considered following the results of the urine Gram stain²⁶¹. When the susceptibility patterns of the causative organisms are known, directed therapy should be changed to narrow-spectrum antibiotics.

If the patient presents with symptoms of mild infection and a urinary origin is unlikely, antimicrobial therapy may be delayed pending urine culture results^{260,282}. Treatment for CA-cystitis is similar to that of non-catheterized patients and narrow-spectrum antimicrobials (FT and NIT) should be used^{1,261}.

Finally, the urinary catheters of patients with CA-UTI should be removed whenever it is feasible to do so, or at least changed as soon as possible. A randomized controlled trial of long-term CA-UTI found that patients who underwent catheter replacement before initiating antimicrobial therapy had significantly higher clinical response rates and a lower incidence of bacteriuria and UTI within 28 days of therapy than those who did not²⁷³.

RECOMMENDATIONS

1. Antimicrobial therapy is indicated for patients with symptomatic infection or clinical signs of sepsis (B-III).
2. Patients with symptomatic UTI and criteria for severe sepsis should be treated with parenteral broad-spectrum antibiotics adapted to the local resistance patterns of uropathogens (C-III). Imipenem, meropenem and piperacillin/tazobactam are the most active antimicrobials in our setting. If the patient has septic shock or resistance to beta-lactams is suspected, combination therapy with amikacin should be considered (C-III).
3. If the patient presents with symptoms of mild infection and a urinary origin is unlikely, antimicrobial therapy can be delayed until the urine culture results are known (C-III).

How long should antimicrobial therapy for CA-UTI last?

The wide spectrum of infections in patients with CA-UTI and the absence of trials with published outcomes of treatment for them make optimal duration of therapy an unresolved issue. Most authors recommend prolonged antimicrobial therapy of between 1 and 2 weeks^{4,260,261}.

However, in order to reduce toxicity and limit the spread of resistance, it is advisable to reduce the length of treatment, especially in mild infections and those that respond promptly to treatment. A randomized study conducted among women with catheter-associated lower UTI following removal of the catheter found similar resolution rates for single-dose and 10-day therapy with COT¹¹⁶. Another study of APN found similar clinical response rates for LVX (750 mg once daily for 5 days) and CIP (500 mg twice daily for 10 days), and a better microbiological response for LVX used to treat CA-UTI patients²⁴⁷. In patients with neurogenic bladders managed by intermittent catheterization, microbiological response to mild CA-UTI was significantly better in those who received CIP for 14 days rather than 3 days²⁸³. FT was found to be effective for treating catheterized patients with cUTI and/or infection caused by MDR bacteria; a 3 gr single-dose therapy and a longer 'off-label' course of FT (3 g every 48-72 h for 7-10 days) have been used for complicated infections²⁸⁴, as well as for cystitis following catheter removal²⁶¹.

Antibiotic prophylaxis is not routinely recommended for catheter placement, removal, or replacement⁴. Traumatic long-term catheter manipulation may be associated with fever and haematuria; bacteremia may be a complication in 4-10% of these episodes^{260,261,263}. These episodes of UTI secondary to catheter placement or removal generally obtain favourable responses after a short course (5-7 days) of antimicrobial therapy, provided that APN and prostatitis have been excluded²⁶¹.

Most experts recommend a short course of antimicrobial therapy (7 days) for patients with CA-UTI whose symptoms resolve promptly, and a longer course (10-14 days) for patients with APN, acute prostatitis, or those with delayed response, regardless of whether or not the catheter is removed. For selected patients, a shorter course of therapy might be as follows: 5 days LVX for mild UTI, and 3 days of antimicrobial therapy or single-dose FT for women with lower tract infection following catheter removal.

RECOMMENDATIONS

1. Seven days is the usual duration of antimicrobial therapy for CA-UTI patients with prompt resolution of symptoms, and patients with cystitis following urinary catheterization (A-III); 10-14 days of treatment is recommended for those with delayed response (A-III), regardless of whether the patient remains catheterized or not.
2. A 5-day course of levofloxacin may be considered for patients with mild CA-UTI (B-III). A 3-day course of antimicrobials (B-II) or a single-dose of fosfomycin trometamol (3 g) (C-III) may be considered for women who develop CA-UTI without upper urinary tract symptoms after removal of an indwelling catheter.
3. Antibiotic prophylaxis should not be administered to patients for catheter placement (E-I) catheter removal (D-I) or replacement (E-III) in order to prevent CA-UTI.

What are the most important measures for prevention of CA-AB and CA-UTI?

Recently published guidelines from multiple institutions and scientific societies have systematically reviewed recommendations for preventing infections associated with urinary catheterization^{4,264,265}. It is noteworthy that these guidelines use different definitions for type of infection, strength of recommendation and the level of evidence of the recommendations. Furthermore, although it is important from a clinical point of view to differentiate between asymptomatic and sUTI, the outcomes of preventive measures have frequently been reported for CA-AB rather than CA-UTI^{4,264,265,285,286}.

Duration of catheterization is the most important risk factor for developing infection and the most important strategy for reducing ASB and UTI is to minimize indwelling catheter use. Catheterization should be used only for approved indications and for the shortest time possible. Several practices for limiting the use and duration of catheterization have been proposed. Alternate methods of catheterization, such as the condom catheter or suprapubic catheter, or intermittent catheterization, have been associated with a lower risk of infection and should be considered whenever possible. The aseptic technique during insertion of the catheter and maintenance of a closed drainage system are universal preventive practices, although there is no evidence about their efficacy during long-term catheterization.

In patients with long-term catheterization, there is no evidence of differential risk for CA-AB or CA-UTI with different catheter materials or antimicrobial-coated catheters. Antibiotic- or silver alloy-coated urinary catheters have been shown to prevent or delay the onset of CA-AB in short-term catheterization, although no decrease in the frequency of CA-UTI or any other clinical benefit has been demonstrated. Widespread use of these catheters in the hospital setting has been limited by their higher cost.

The use of systemic antimicrobials is associated with decreased frequency of CA-AB during the first days of catheterization, but no long-term clinical benefit has been shown and there is a greater risk of developing antimicrobial resistance. A recent meta-analysis found a

decreased frequency of sUTI among patients receiving antibiotic prophylaxis following short-term catheter removal²⁸⁷, although no published guidelines have made other up-to-date recommendations for this specific situation. Routine catheter change is not recommended for patients with chronic indwelling urethral catheters, because it has not been shown to be beneficial for preventing infection. The catheter should only be changed when there is catheter obstruction, damage or malfunction, or before treatment for CA-UTI.

RECOMMENDATIONS

1. Indwelling catheters should be placed only when they indicated (A-III) and should be removed as soon as they are no longer required, in order to reduce the risk of CA-AB (A-I) and CA-UTI (A-II). Indwelling catheters should be inserted using the aseptic technique and sterile equipment (B-III) and a closed catheter drainage system should be maintained to reduce CA-AB and CA-UTI (A-II and A-III, respectively, for patients with short-term catheters; A-III and A-III, respectively, for patients with long-term catheters).
2. Appropriate alternatives to short- and long-term urethral catheterization should be considered for reducing CA-AB, such as condom catheterization (A-II and B-II, respectively) intermittent catheterization (C-I and A-III, respectively), and suprapubic catheterization (B-I for short-term catheterization). Alternatives for reducing CA-UTI are intermittent catheterization (C-III for short-term and A-III for long-term catheterization) and suprapubic catheterization (C-III for short-term catheterization)
3. In patients with short-term indwelling urethral catheterization, antimicrobial (antibiotic or silver alloy)-coated urinary catheters may reduce or delay the onset of CA-AB, but does not decrease the frequency of CA-UTI (B-II).
4. Systemic antibiotic prophylaxis should not be routinely used to reduce CA-AB or CA-UTI in patients with short-term (A-III) or long-term (A-II) catheterization because of the concern of selection of antimicrobial resistance.

Risk factors and prevention strategies for recurrent urinary tract infections (rUTI)

Recurrent UTI, defined as three episodes of UTI in the previous 12 months or two episodes in the previous six months, are common in women^{191,288,289}. Distinguishing between relapse and reinfection is essential for determining an approach to diagnosis and therapy. *Relapse* represents 20% of rUTI and is due to the persistence and reappearance of the original infecting strain, generally within the first 2-3 weeks of an apparent cure. The various possible reasons for a relapse include short or inadequate antibiotic treatment, quiescent bacterial reservoirs of the causative organism due to coexistence of an underlying urological disease (renal calculi, the presence of a catheter that has not been withdrawn, or chronic prostatitis) which is diagnosed by performing a proper urological study.

Reinfection accounts for 80% of rUTI cases. These represent new UTIs caused by a different strain from the original one, although they may also be caused by the same strain persisting in the gastrointestinal tract. They occur mainly in sexually active young women, post-menopausal women and patients with certain urological disorders, such as urinary incontinence, cystoceles, patients with neurogenic bladders or a history of previous gynecological surgery. Reinfections usually occur later than relapses (usually more than two weeks after the initial UTI) and may be prevented by following some of the different strategies discussed in these guidelines.

Recurrent UTI in men is usually due to a urological abnormality (obstructive uropathy due to prostatic hypertrophy is the most common one) or to a chronic prostatitis and requires a different clinical approach and will not be discussed in this guideline.

What are the main risk factors of rUTI in premenopausal women?

The high frequency of rUTI in women has been associated with: a) anatomical factors, such as the shorter female urethra and its proximity to the vagina, which favors intestinal colonization with Enterobacteriaceae; b) genetic factors that determine increased adherence by Enterobacteriaceae to vaginal and uroepithelial cells, and explain why there is a family propensity to recurrent infection^{191,288}. It has been demonstrated that the uroepithelial cells of patients who are non-secretors of ABO blood group antigens are more susceptible to enhanced adhesion of uropathogenic isolates than secretors. It has also been suggested that expression of the P blood group phenotype predisposes to recurrent pyelonephritis. The interleukin-8 receptor (CXCR1) is another genetic factor that may influence the development of UTI since CXCR1 expression is significantly lower in the pyelonephritis-prone children than in controls^{191,288}; c) behavioral factors, with the main risk factor being frequency of sexual intercourse. A study published in 2000 demonstrated that there was a 9 times greater risk of rUTI with daily sexual intercourse²⁹⁰. Other behavioral factors associated with rUTI are intercourse before the age of 15 years, use of spermicidal creams (it reduces vaginal concentrations of lactobacilli), a recent change of sexual partner (which could lead to an increase in sexual activity) or recent antibiotic consumption²⁹¹. In this group of patients, the presence of an underlying urological disease is rarely responsible for rUTI, so that a urological diagnostic test is not indicated if there is no suggestive medical history (UTI in infancy, haematuria with passage of blood clots, suspicion of neurogenic bladder, nephrolithiasis or relapse). Four different studies have demonstrated that, in the absence of the previous conditions, carrying out urological diagnostic tests has a low diagnostic yield and is not cost-effective^{292–295}.

RECOMMENDATIONS

1. In sexually active women, the main risk factor for rUTI is frequency of sexual intercourse (B-I).
2. In sexually active women with rUTI, it is not necessary to perform a urological study if there is no suspicion of underlying urological disease (A-II).

Are hygienic measures effective in preventing rUTI?

The traditional advice of high fluid intake, frequent urination, post-coital urination and maintaining hygienic habits after bowel movements often fails in patients with rUTI and there is in fact some evidence that these measures are not effective in women with rUTI^{290,296}. This does not mean that they may not be useful for patients with isolated episodes of cystitis.

RECOMMENDATION

1. In women who fail to prevent rUTI with hygiene measures, it is not necessary to insist on their implementation (B-II).

Is acidification of the urine useful for preventing rUTI?

It has been suggested that ascorbic acid may be useful for acidifying the urine and preventing rUTI, although 2 g doses of vitamin C have not proved to be effective²⁹⁷ due to rapid clearance, while more frequent dosing intervals (every 2-4 h) are unacceptable in daily practice^{288,289}.

Methenamine salts acidify the urine by producing formaldehyde. In a meta-analysis of 13 studies, methenamine hippurate, a preparation not available in Spain, reduced rates of rUTI (RR = 0.24) in patients with no urological abnormalities, although not in patients with urinary catheters or urinary tract disorders²⁹⁸. In 2011, it was declared to be carcinogenic, with a theoretical risk of causing tumours in the urinary tract. We agree therefore that this strategy should not be used for prolonged periods²⁸⁹.

RECOMMENDATIONS

1. Vitamin C (ascorbic acid) in acceptable dosing intervals in regular clinical practice is not useful in the prevention of rUTI (B-II).
2. Although methenamine hippurate is useful for preventing rUTI (B-I), we do not recommend its use, given the potential carcinogenic risks (C-III).

When is it advisable to use prevention strategies?

In women with few UTIs per year (<3 per year) and patients who wish to take fewer antibiotics, self-treatment of cystitis with antibiotics previously prescribed by a physician can be used. Three studies showed that, in patients with sufficient intellectual capacity, self-diagnosed cystitis was correctly cured in approximately 90% of cases²⁹⁹⁻³⁰¹. Clinical and microbiological cure rates using COT or FQs (ofloxacin, LVX) were above 90%. Only 6% of these patients subsequently required continuous antibiotic prophylaxis. Although patients who adopt this therapeutic strategy have more sUTIs than those who use continuous or post-coital antibiotic prophylaxis, self-administered antimicrobials reduce the symptoms quickly. This strategy is not recommended for patients at increased risk of sexually transmitted diseases, because it can delay the diagnosis and treatment of such infections.

In patients with rUTI, any of the following different strategies can be recommended: continuous or post-coital antibiotic prophylaxis, topical vaginal estrogens, cranberries, vaccines and D-Mannose. All these strategies have been shown to lead to a significant reduction in the incidence of recurrent urinary tract infections^{191,288,289}. The choice of one or other strategy will depend on such aspects as the number of rUTI, its relation to sexual activity, menopausal state or not, individual preferences (e.g. reluctance to take antibiotics), possible side effects, risk of selection of resistance, previous strategy failure, and costs (some preparations are not financed by the Spanish Social Security System)²⁸⁸.

Before any preventive strategy can be implemented, the most recent UTI must be eradicated. Most published studies apply preventive strategies for a period of 6 months.

RECOMMENDATIONS

1. In women with fewer than 3 UTIs per year, self-treatment of cystitis is a convenient and effective measure and also reduces the consumption of antibiotics associated with prophylaxis (B-II).

2. The administration of continuous (A-I) or post-coital (A-I) antibiotics, topical vaginal estrogens (A-I), cranberries (A-II) or D-Mannose (A-II) for a 6-month period reduces the frequency of rUTI to a greater or lesser extent.

What is the efficacy of continuous or post-coital antibiotic prophylaxis?

Numerous randomized, placebo-controlled studies have shown that continuous prophylaxis with a low dose of antibiotics significantly reduces rUTI^{191,288,289,302,303}. It has been suggested that prophylactic action can occur by three mechanisms of action: reducing concentrations of uropathogenic Enterobacteriaceae in fecal and vaginal reservoirs, intermittent urine sterilization, and inhibition of bacterial adhesion to bladder mucosal cells by sub-inhibitory concentrations of antimicrobial agents. Table 11 shows the antibiotics mainly used and their dosages. In two meta-analyses of placebo-controlled trials^{302,303}, the administration of antibiotic prophylaxis for 6-12 months reduced clinical recurrence by 85% and microbiological recurrence by 78%, but increased the risk of oral and vaginal candidiasis. In six studies comparing two antibiotics, neither antibiotic showed superiority. After the meta-analyses were published, a randomized study with placebo, which administered 3 g of FT every 10 days for 6 months, similarly reduced the number of recurrences³⁰⁴. In elderly patients, this standard pattern is generally given weekly to facilitate compliance.

Given the presence of side effects, the risk of vaginal candidiasis, cost and the impact on resistance, the most recommended prophylactic options are FT, COT and NIT^{44,191,288}. FQs should be reserved as the last option for prophylaxis, given their impact on resistance and the possibility of undesirable effects associated with them (*Clostridium difficile*-associated diarrhea). Continuous prophylaxis with a low dose of antibiotic to be taken every night is usually indicated for patients with frequent rUTI not clearly related to sexual intercourse, or when intercourse is very frequent. Most authors recommend administering antibiotic prophylaxis at night for a minimum of 6 months. If UTI recurs after cessation of prophylaxis, prolonged prophylactic therapy for 1 or 2 years or even longer, is recommended. This treatment strategy is effective in clinical practice, although there are no studies of its actual effectiveness^{191,288,289}. The administration of low doses of COT or other agents for periods exceeding 5 years has proven to be effective and well tolerated.

NIT can cause neurotoxicity, pulmonary (acute hypersensitivity pneumonitis and chronic pulmonary fibrosis) and hepatotoxicity, particularly with prolonged exposure. Although the incidence of such adverse effects is low (0.13 to 0.0001% for pulmonary reactions and 0.0003% for hepatic reactions, clinical monitoring is recommended for the presence of respiratory and gastrointestinal symptoms^{175,305,306}. Due to these side effects, recently the AEMPs (Spanish Drug Agency), has recommended to avoid prolonged treatment (>7 days) with NIT. No specific recommendations against the use for NIT in prolonged therapy (6 months) for prophylaxis for rUTI have been made by the FDA and the EMA (European Medicines Agency).

Increased resistance rates may have modified the effectiveness of these antibiotic regimens; however, monitoring the rectal or vaginal flora to detect the presence of resistant organisms does not predict the development of recurrence^{288,289}.

Post-coital prophylaxis is a useful therapeutic strategy for patients where UTI is related to sexual activity. Continuous prophylaxis, especially with 3 g FT administered every 7-10 days, is probably more comfortable for women with highly frequent sexual intercourse.

In placebo-controlled studies, post-coital administration of COT, FQs, NIT and cephalexin (table 11) reduced reinfection rates to percentages similar to those of continuous prophylaxis^{191,288,302}. In the only comparative study, post-coital administration of CIP prophylaxis was as effective as continuous prophylaxis³⁰⁷. FQs should be reserved as the last prophylactic option, given their impact on resistance.

RECOMMENDATIONS

1. In women with rUTI, continuous or post-coital antibiotic prophylaxis administered for 6-12 months is highly effective for reducing recurrence (A-I).
2. The effectiveness of the different antibiotics used in prophylaxis (COT, NIT, trimethoprim, FQs and cephalosporins) is similar (B-II).
3. If UTI recurs after cessation of prophylaxis, it is recommended to restart the same prophylaxis regimen for a longer period (1-2 years) (C-III).
4. Due to its ecological impact, prophylaxis with FQs should be used only when no other preventive strategy is available (C-III).

What is the role of cranberries in preventing rUTI? Is antibiotic prophylaxis more effective than cranberries in the prevention of rUTI?

Cranberries are a traditional remedy for prevention of rUTI, but have neither the antimicrobial properties nor sufficient capacity to acidify the urine. However, cranberries inhibit the adhesion of uropathogens to urothelial cells mainly due to 2 mechanisms: Through their high fructose content, which inhibits enterobacterial type 1 fimbriae and proanthocyanidins (PAC) that inhibit the adhesion of P-fimbriated uropathogens^{191,288,308}. It is difficult to summarize the literature because some of the studies are of poor quality, the dosages and administration methods vary, and some meta-analyses include patients with few episodes of UTI and so do not fulfill the criteria for rUTI³⁰⁹. In the first meta-analysis³¹⁰, which included only rUTI patients, cranberries administered for 6-12 months effectively reduced the incidence of UTI by 35%, except in patients with urinary catheterization (in this group only 10% of UTIs were caused by uropathogens with fimbriae). A more recent meta-analysis³¹¹, which included 13 studies with 1,616 patients, observed an overall efficacy of 38%. When broken down by subgroups, efficacy was higher in women with rUTI (a 47% reduction in the rate of UTI) and children (63 %); cranberries, however, were not effective for patients with few UTIs.

Two randomized studies compared the efficacy of antibiotic prophylaxis using cranberries. In one, a similar efficacy to TMP was observed, but with fewer side effects³¹². Another recent study including 221 patients with frequent reinfection demonstrated that administration of low doses of COT (80/400 mg) was more effective than cranberries ($p < 0.02$), although in the cranberry group, antibiotic resistance rates did not increase³⁰⁸.

The optimal dose of PAC is not yet clear. Although the French Agency for Food Safety recommends a minimum of 36 mg daily, it has been experimentally observed that 72 mg has greater capacity to inhibit adhesion³¹³. In any case, in our country, most commercial preparations today contain more than 100 mg of PAC. The side effects of administering cranberries are few and mostly digestive.

RECOMMENDATIONS

1. Cranberries administered for 6-12 months are moderately effective in preventing new episodes of UTI in patients with rUTI (A-I); in patients with few UTIs, they are not effective (A-II).
2. Antibiotic prophylaxis is more effective than cranberries (A-I).
3. A 72 mg dose, or higher, of PAC is recommended (C-III).

What are the main predisposing factors in postmenopausal women?

rUTI is relatively common in postmenopausal women, with between 15-20% of women over 60 presenting recurrence. This percentage is higher among institutionalized patients.

One case-control study showed that anatomical or functional factors affecting the emptying of the bladder were the main factors associated with recurrence. Factors associated with rUTI were: urinary incontinence (41% vs. 9%, OR, 5.79), presence of a cystocele (19% vs. 0%), presence of post-void residual urine (28% vs. 2%), a history of UTI before menopause (OR, 4.85), non-secretion of ABO blood group antigens (OR, 2.9) and previous gynecological surgery³¹⁴. The risk of recurrence was 6.9 times higher when diabetes mellitus was present²⁹⁶. Post-operative urinary obstruction leading to significant post-void residual urine should be suspected in patients who undergo surgery for urinary incontinence, followed by initiation of rUTI. A frequent cause of recurrence in post-menopausal women is the presence of post-void residual urine due to a neurogenic bladder, which may go unnoticed if urodynamic tests are not performed. This alteration is also frequently responsible for recurrence in patients with neurological disease. Among the elderly, residence in a nursing home, urinary catheterization and exposure to antimicrobials are other factors associated with rUTI³¹⁵. In postmenopausal patients, less is known about the role of sexual habits. In a study involving 899 healthy women and 911 UTI patients, it was observed that patients with UTI were more often sexually active (OR, 1.42), had diabetes (OR, 2.78), a previous history of UTI (OR, 4.2) or urinary incontinence (OR, 1.36)³¹⁶.

In postmenopausal women with rUTI unrelated to urological disease, recurrence could also be related to low levels of vaginal estrogen. This would imply decreasing levels of vaginal glycogen and secondarily of *Lactobacillus* spp, thus promoting vaginal colonization with Enterobacteriaceae.²⁶⁹

RECOMMENDATIONS

1. In menopausal women without neurological diseases, the main risk factors for suffering rUTI are urinary incontinence, previous gynaecological surgery, presence of diabetes mellitus, a cystocele, residual urine and a history of rUTI before menopause (B-II).
2. The role of sexual activity is less relevant as a predisposing factor for recurrence in postmenopausal women (B-II).

What is the effectiveness of topical vaginal estrogens preventing rUTI?

A meta-analysis including 9 studies showed that administration of oral estrogens does not reduce rUTIs and increases cardiovascular and thromboembolic events and the risk of breast cancer³¹⁷. Topical vaginal estrogens restore the vaginal flora, reduce vaginal atrophy, vaginal

pH and number of rUTIs. In this respect, some studies found that a topically applied intravaginal estriol cream reduced rUTI by 75-80%^{317,318}.

It is not known whether antibiotic prophylaxis is superior to topical estrogen. In a comparative study with nitrofurantoin, antibiotic prophylaxis was more effective³¹⁹, and in another, vaginal estrogen was more effective³¹⁷.

RECOMMENDATIONS

1. Oral administration of estrogen does not reduce rUTI (E-I).
2. Vaginal estrogen significantly reduces rUTI (A-II).
3. It is not known whether antibiotic prophylaxis is more efficacious than vaginal creams (C-II).
4. Vaginal estrogen administration is the prophylaxis of choice when associated with vaginal atrophy and should always be considered in all postmenopausal patients (C-III).

Are vaccines useful in the prevention of rUTI?

The intravaginal administration of vaccines using heat-inactivated pathogenic strains has a partial and transitory protective effect; between 5-28% women experience vaginal irritation after application^{191,288,289}.

Parenterally administered vaccines based on type 1 fimbriae looked promising almost 20 years ago, but so far there have been no clinical studies of humans²⁸⁸.

Oral or intranasal vaccines using various bacterial extracts from uropathogenic strains are attractive. It has been suggested that they have multifactorial action. These vaccines stimulate innate immunity, activating the phagocytic activity of macrophages and cytokine production. Furthermore, they activate T helper cells that stimulate secretion of IgG and IgA in the mucosa associated lymphoid tissue (MALT) along the urinary mucosa, blocking bacterial adhesion²⁸⁸.

The Uro-Vaxom (OM-89) vaccine, an extract of 18 different serotypes of urinary pathogens, is the most studied vaccine. In a meta-analysis that included five placebo-controlled studies, this vaccine showed a 40% reduction in rUTIs³²⁰. In another recent meta-analysis of 5 heterogeneous randomized studies, the efficacy of the vaccine was limited to a period of 6 months³²¹. This vaccine is not commercialized in Spain. There are no appropriate studies assessing the effectiveness of other similar vaccines commercialized in our country. Furthermore, there have been no studies to evaluate the indication for re-vaccinating patients following loss of effectiveness and the reappearance of rUTI after 6 months of exposure.

RECOMMENDATIONS

1. Oral and intranasal vaccines (OM-89) made from uropathogenic bacterial extracts are moderately effective in preventing rUTI (B-II).
2. There are no adequate studies assessing the effectiveness of other commercialized preparations (C-III).

Other prevention strategies

Intravaginal administration of probiotics like lactobacillus is an old and attractive option, although it is difficult to retain the organism in the vagina over a long period of time. Lactobacilli exert activity by maintaining a low vaginal pH, hampering the adhesion of uropathogens, secreting hydrogen peroxide (a microbicide) and stimulating the secretion of cytokines¹⁹¹. However, in a review of four randomized studies, only one showed a reduction in the number of rUTIs³²². More appropriate studies are required before it can be recommended for application in daily clinical practice.

Other alternative strategies, of which there is limited experience or are difficult to apply, include intravesical hyaluronic acid instillation and use of avirulent strains of *E. coli*. D-mannose, a monosaccharide present in the Tamm-Horsfall glycoprotein that binds mainly to the type 1 fimbriae (or pili) of uropathogens, acts by preventing them from adhering to specific urothelial receptors. In a comparative prospective randomized study that included one hundred patients in each group, both D-mannose (2,000 mg/daily) and NIT (50 mg/daily) statistically reduced the number of rUTI compared to placebo group. Furthermore, there were no statistically significant differences in effectiveness between the D-mannose group and NIT at 6 months of follow-up (14.6% vs. 20.4% in recurrent UTI)³²³.

It is currently unknown whether combinations of any of these strategies are more effective than when used individually.

RECOMMENDATIONS

1. There is insufficient evidence to recommend vaginal application of lactobacilli as a strategy for preventing rUTI (B-II).
2. D-mannose is effective in preventing rUTI (A-II). Its effectiveness is similar to nitrofurantoin for this indication (A-II).

Conflict of interest and funding

The authors and reviewers have not received any aid or grant related to this document. SEIMC has no influence on the elaboration of the guidelines.

References

1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011;52:e103–20.
2. Sobel JD, Kaye D. Urinary tract infections. In: Bennett J, Dolin R, Blaser M, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier; 2015. p. 886–913.
3. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*. 2005;40:643–54.
4. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50:625–63.

5. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. *Eur Urol*. 2008;54:1164–75.
6. Palou J, Pigrau C, Molina I, Ledesma JM, Angulo J. Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy. *Med Clin (Barc)*. 2011 Jan 15;136:1–7.
7. Andreu A, Planells I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of *Escherichia coli*: a national surveillance study. *Med Clin (Barc)*. 2008;130:481–6.
8. Lane DR, Takhar SS. Diagnosis and management of urinary tract infection and pyelonephritis. *Emerg Med Clin North Am*. 2011;29:539–52.
9. Drekonja DM, Johnson JR. Urinary tract infections. *Prim Care*. 2008;35:345–67, vii.
10. Nicolle LE. Update in adult urinary tract infection. *Curr Infect Dis Rep*. 2011;13:552–60.
11. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. *J Antimicrob Chemother*. 2003;51:69–76.
12. Bouza E, San Juan R, Muñoz P, Voss A, Kluytmans J. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. *Clin Microbiol Infect*. 2001;7:532–42.
13. McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. *Am J Med*. 1999;106:292–9.
14. McNulty CAM, Richards J, Livermore DM, Little P, Charlett A, Freeman E, et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. *J Antimicrob Chemother*. 2006;58:1000–8.
15. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA*. 2000;283:1583–90.
16. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant *Escherichia coli* infection among emergency department patients with pyelonephritis. *Clin Infect Dis*. 2008;47:1150–8.
17. Alós J-I, Serrano M-G, Gómez-Garcés J-L, Perianes J. Antibiotic resistance of *Escherichia coli* from community-acquired urinary tract infections in relation to demographic and clinical data. *Clin Microbiol Infect*. 2005;11:199–203.
18. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med*. 2012;366:1028–37.
19. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? *JAMA*. 2002;287:2701–10.
20. Little P, Moore M V, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. *BMJ*. 2010;340:c199.
21. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. *JAMA*. 2014;312:1677–84.

22. Gupta K, Trautner B. In the clinic. Urinary tract infection. *Ann Intern Med*. 2012;156:ITC3–1.
23. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. *Urol Clin North Am*. 2008;35:1–12.
24. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis*. 2004;38:1150–8.
25. Nicolle LE. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol*. 2005;16:349–60.
26. Blanco J, Mora A, Mamani R, López C, Blanco M, Dahbi G, et al. National survey of *Escherichia coli* causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. *J Antimicrob Chemother*. 2011;66:2011–21.
27. Rogers BA, Sidjabat HE, Paterson DL. *Escherichia coli* O25b-ST131: a pandemic, multiresistant, community-associated strain. *J Antimicrob Chemother*. 2011;66:1–14.
28. Hooton TM. The current management strategies for community-acquired urinary tract infection. *Infect Dis Clin North Am*. 2003;17:303–32.
29. McMurray BR, Wrenn KD, Wright SW. Usefulness of blood cultures in pyelonephritis. *Am J Emerg Med*. 1997;15:137–40.
30. Pasternak E, Topinka M. Blood cultures in pyelonephritis: Do results change therapy? *Acad Emerg Med*. 2000;7:1170.
31. Chen Y, Nitzan O, Saliba W, Chazan B, Colodner R, Raz R. Are blood cultures necessary in the management of women with complicated pyelonephritis? *J Infect*. 2006;53:235–40.
32. Velasco M, Martínez JA, Moreno-Martínez A, Horcajada JP, Ruiz J, Barranco M, et al. Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? *Clin Infect Dis*. 2003;37:1127–30.
33. Ledochowski S, Abraham P-S, Jacob X, Dumitrescu O, Lina G, Lepape A, et al. Relevance of blood cultures in acute pyelonephritis in a single-center retrospective study. *Intern Emerg Med*. 2015;10:607–12.
34. Wing DA, Park AS, Debuque L, Millar LK. Limited clinical utility of blood and urine cultures in the treatment of acute pyelonephritis during pregnancy. *Am J Obstet Gynecol*. 2000;182:1437–40.
35. Gomi H, Goto Y, Laopaiboon M, Usui R, Mori R. Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes. *Cochrane database Syst Rev*. 2015;2:CD009216.
36. Spoorenberg V, Prins JM, Opmeer BC, de Reijke TM, Hulscher MEJL, Geerlings SE. The additional value of blood cultures in patients with complicated urinary tract infections. *Clin Microbiol Infect*. 2014;20:O476–9.
37. Hsu C-Y, Fang H-C, Chou K-J, Chen C-L, Lee P-T, Chung H-M. The clinical impact of bacteremia in complicated acute pyelonephritis. *Am J Med Sci*. 2006;332:175–80.
38. Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. *AMA Arch Intern Med*. 1957;100:709–14.
39. Kass EH. Bacteriuria and pyelonephritis of pregnancy. *Arch Intern Med*. 1960;105:194–8.
40. Stamm WE, Hooton TM. Management of urinary tract infections in adults. *N Engl J Med*. 1993;329:1328–34.
41. Kunin C. Bacteriuria, pyuria, proteinuria, hematuria y pneumaturia. In: Cunin C,

- editor. Urinary tract infection. Detection, prevention and management. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 2–21.
42. Kunin CM, White LV, Hua TH. A reassessment of the importance of “low-count” bacteriuria in young women with acute urinary symptoms. *Ann Intern Med*. 1993;119:454–60.
43. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. *N Engl J Med*. 2013;369:1883–91.
44. Grabe M, Bartoletti R, Bjerklund-Johansen T, Cai T, Cek M, Koves B, et al. Guidelines on urological infection. 2015. European Association of Urology [Internet]. Available from: http://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf
45. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. *Clin Infect Dis*. 1992;15 Suppl 1:S216–27.
46. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. *Int J Antimicrob Agents*. 2002;19:546–53.
47. Wagenlehner FME, Naber KG. Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles. *Expert Rev Anti Infect Ther*. 2004;2:923–31.
48. Labreche MJ, Graber CJ, Nguyen HM. Recent updates on the role of pharmacokinetics-pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice. *Clin Infect Dis*. 2015;61:1446–52.
49. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. *Pediatr Infect Dis J*. 2003;22:982–92.
50. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. *Clin Microbiol Rev*. 2007;20:391–408.
51. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Five Informational Supplement. CLSI document M100-S25. Wayne, PA, USA, 2015.
52. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 5. Available at: <http://www.eucast.org>. Accessed 1 November 2015.
53. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. *N Engl J Med*. 1974;291:1159–63.
54. Martinelli R, Lopes AA, de Oliveira MM, Rocha H. Amoxicillin-clavulanic acid in treatment of urinary tract infection due to gram-negative bacteria resistant to penicillin. *Antimicrob Agents Chemother*. 1981;20:800–2.
55. Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN, Frimodt-Møller N. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. *Antimicrob Agents Chemother*. 2000;44:156–63.
56. Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. *Int J Antimicrob Agents*. 2006;28 Suppl 1:S35–41.
57. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. *Diagn Microbiol Infect Dis*. 2007;58:337–44.
58. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative

aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. *J Antimicrob Chemother.* 2008;61:621–8.

59. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. *Clin Microbiol Infect.* 2001;7:589–96.
60. Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. *Antimicrob Agents Chemother.* 2009;53:3462–71.
61. Mignini L, Carroli G, Abalos E, Widmer M, Amigot S, Nardin JM, et al. Accuracy of diagnostic tests to detect asymptomatic bacteriuria during pregnancy. *Obstet Gynecol.* 2009 Feb;113(2 Pt 1):346–52.
62. Whalley P. Bacteriuria of pregnancy. *Am J Obstet Gynecol.* 1967;97:723–38.
63. Hill JB, Sheffield JS, McIntire DD, Wendel GD. Acute pyelonephritis in pregnancy. *Obstet Gynecol.* 2005;105:18–23.
64. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. *Am J Obstet Gynecol.* 2014;210:219.e1–6.
65. Kass EH. The role of asymptomatic bacteriuria in the pathogenesis of pyelonephritis. In: Quin E, Kass E, editors. *Biology of pyelonephritis*. Boston: Little Brown and Company; 1960. p. 399–412.
66. Meis PJ, Michielutte R, Peters TJ, Wells HB, Sands RE, Coles EC, et al. Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis. *Am J Obstet Gynecol.* 1995;173:590–6.
67. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. *Cochrane database Syst Rev.* 2015;8:CD000490.
68. Brumfitt W. The effects of bacteriuria in pregnancy on maternal and fetal health. *Kidney Int Suppl.* 1975;4:S113–9.
69. Elder HA, Santamarina BA, Smith SA, Kass EH. Use of sulfasymazine in the treatment of bacteriuria of pregnancy. *Antimicrob Agents Chemother.* 1966;6:142–8.
70. Elder HA, Santamarina BA, Smith S, Kass EH. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. *Am J Obstet Gynecol.* 1971;111:441–62.
71. Foley ME, Farquharson R, Stronge JM. Is screening for bacteriuria in pregnancy worthwhile? *Br Med J (Clin Res Ed).* 1987;295:270.
72. Furness ET, McDonald PJ, Beasley NV. Urinary antiseptics in asymptomatic bacteriuria of pregnancy. *N Z Med J.* 1975;81:417–9.
73. Gold EM, Traub FB, Daichman I, Terris M. Asymptomatic bacteriuria during pregnancy. *Obstet Gynecol.* 1966;27:206–9.
74. Kincaid-Smith P, Bullen M. Bacteriuria in pregnancy. *Lancet.* 1965;1:395–9.
75. Little PJ. The incidence of urinary infection in 5000 pregnant women. *Lancet.* 1966;2:925–8.
76. Pathak UN, Tang K, Williams LL, Stuart KL. Bacteriuria of pregnancy: results of treatment. *J Infect Dis.* 1969;120:91–103.
77. Williams GL, Campbell H, Davies KJ. Urinary concentrating ability in women with asymptomatic bacteriuria in pregnancy. *Br Med J.* 1969;3:212–5.
78. Wren BG. Subclinical renal infection in pregnancy; pathogenesis, the organisms and the drugs of choice in its treatment. *Med J Aust.* 1969;2:895–8.
79. Savage WE, Hajj SN, Kass EH. Demographic and prognostic characteristics of

bacteriuria in pregnancy. *Medicine (Baltimore)*. 1967;46:385–407.

80. Leblanc AL, McGanity WJ. The impact of bacteriuria in pregnancy; a survey of 1300 pregnant patients. *Tex Rep Biol Med*. 1964;22:336–47.

81. Kazemier BM, Koningstein FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. *Lancet Infect Dis*. 2015;15:1324–33.

82. Nicolle LE. Management of asymptomatic bacteriuria in pregnant women. *Lancet Infect Dis*. 2015;15:1252–4.

83. Thomsen AC, Mørup L, Hansen KB. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. *Lancet*. 1987;1:591–3.

84. Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. *Obstet Gynecol*. 1989;73:576–82.

85. Melchor Marcos J, Uceda Somoza R. Infección urinaria en la mujer embarazada. In: Pigrau C, editor. *Infección del tracto urinario*. Madrid: Ergon; 2013. p. 73–84.

86. Stenqvist K, Dahlén-Nilsson I, Lidin-Janson G, Lincoln K, Odén A, Rignell S, et al. Bacteriuria in pregnancy. Frequency and risk of acquisition. *Am J Epidemiol*. 1989;129:372–9.

87. Gratacós E, Torres PJ, Vila J, Alonso PL, Cararach V. Screening and treatment of asymptomatic bacteriuria in pregnancy prevent pyelonephritis. *J Infect Dis*. 1994;169:1390–2.

88. Grabe M. Antimicrobial agents in transurethral prostatic resection. *J Urol*. 1987;138:245–52.

89. Cafferkey MT, Falkiner FR, Gillespie WA, Murphy DM. Antibiotics for the prevention of septicaemia in urology. *J Antimicrob Chemother*. 1982;9:471–7.

90. Grabe M, Forsgren A, Björk T, Hellsten S. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. *Eur J Clin Microbiol*. 1987;6:11–7.

91. Olsen JH, Friis-Møller A, Jensen SK, Korner B, Hvidt V. Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine. *Scand J Urol Nephrol*. 1983;17:299–301.

92. Grabe M, Forsgren A, Hellsten S. The effect of a short antibiotic course in transurethral prostatic resection. *Scand J Urol Nephrol*. 1984;18:37–42.

93. Allan WR, Kumar A. Prophylactic mezlocillin for transurethral prostatectomy. *Br J Urol*. 1985;57:46–9.

94. Yang L, Gao L, Chen Y, Tang Z, Liu L, Han P, et al. Prophylactic antibiotics in prostate biopsy: A meta-analysis based on randomized controlled trials. *Surg Infect (Larchmt)*. 2015;16:733–47.

95. Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J. Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. *J Urol*. 1991;146:955–60.

96. Wolf JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ. Best practice policy statement on urologic surgery antimicrobial prophylaxis. *J Urol*. 2008;179:1379–90.

97. El Basri A, Petrolekas A, Cariou G, Doublet JD, Hoznek A, Bruyere F. Clinical significance of routine urinary bacterial culture after transurethral surgery: results of a prospective multicenter study. *Urology*. 2012;79:564–9.

98. Latthe PM, Foon R, Tooze-Hobson P. Prophylactic antibiotics in urodynamics: a systematic review of effectiveness and safety. *Neurourol Urodyn*. 2008;27:167–73.
99. Guía de práctica clínica de la SEGO. Diagnóstico y tratamiento de la infección urinaria en la mujer con patología del suelo pélvico. Barcelona: Zambon; 2015.
100. Herr HW. Outpatient urological procedures in antibiotic-naïve patients with bladder cancer with asymptomatic bacteriuria. *BJU Int*. 2012;110:E658–60.
101. Dass AK, Lo T-S, Khanuengkitkong S, Tan Y-L. Bacteriuria and safety of female urodynamic studies. *Int Urogynecol J*. 2013;24:677–82.
102. Bregenzer T, Frei R, Widmer AF, Seiler W, Probst W, Mattarelli G, et al. Low risk of bacteremia during catheter replacement in patients with long-term urinary catheters. *Arch Intern Med*. 1997;157:521–5.
103. Jewes LA, Gillespie WA, Leadbetter A, Myers B, Simpson RA, Stower MJ, et al. Bacteriuria and bacteraemia in patients with long-term indwelling catheters—a domiciliary study. *J Med Microbiol*. 1988;26:61–5.
104. Lin K, Fajardo K. Screening for asymptomatic bacteriuria in adults: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*. 2008;149:W20–4.
105. Asscher AW, Sussman M, Waters WE, Evans JA, Campbell H, Evans KT, et al. The clinical significance of asymptomatic bacteriuria in the nonpregnant woman. *J Infect Dis*. 1969;120:17–26.
106. Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D’Elia C, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? *Clin Infect Dis*. 2012;55:771–7.
107. Cai T, Nesi G, Mazzoli S, Meacci F, Lanzafame P, Caciagli P, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. *Clin Infect Dis*. 2015;61:1655–61.
108. Bengtsson C, Bengtsson U, Björkelund C, Lincoln K, Sigurdsson JA. Bacteriuria in a population sample of women: 24-year follow-up study. Results from the prospective population-based study of women in Gothenburg, Sweden. *Scand J Urol Nephrol*. 1998;32:284–9.
109. Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. *Clin Infect Dis*. 1995;21:316–22.
110. Nicolle LE. Urinary tract infections in special populations: diabetes, renal transplant, HIV infection, and spinal cord injury. *Infect Dis Clin North Am*. 2014;28:91–104.
111. Harding GKM, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. *N Engl J Med*. 2002;347:1576–83.
112. Forland M, Thomas V, Shelokov A. Urinary tract infections in patients with diabetes mellitus. Studies on antibody coating of bacteria. *JAMA*. 1977;238:1924–6.
113. Forland M, Thomas VL. The treatment of urinary tract infections in women with diabetes mellitus. *Diabetes Care*. 1985;8:499–506.
114. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med*. 2000;160:678–82.
115. Leone M, Perrin A-S, Granier I, Visintini P, Blasco V, Antonini F, et al. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. *Intensive Care Med*. 2007;33:726–9.

116. Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE, et al. How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. *Ann Intern Med*. 1991;114:713–9.
117. Alling B, Brandberg A, Seeberg S, Svanborg A. Effect of consecutive antibacterial therapy on bacteriuria in hospitalized geriatric patients. *Scand J Infect Dis*. 1975;7:201–7.
118. Warren JW, Anthony WC, Hoopes JM, Muncie HL. Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. *JAMA*. 1982;248:454–8.
119. Trautner BW, Grigoryan L. Approach to a positive urine culture in a patient without urinary symptoms. *Infect Dis Clin North Am*. 2014;28:15–31.
120. Polastri F, Auckenthaler R, Loew F, Michel JP, Lew DP. Absence of significant bacteremia during urinary catheter manipulation in patients with chronic indwelling catheters. *J Am Geriatr Soc*. 1990;38:1203–8.
121. Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. *Infect Dis Clin North Am*. 2003;17:367–94.
122. Abrutyn E, Berlin J, Mossey J, Pitsakis P, Levison M, Kaye D. Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? *J Am Geriatr Soc*. 1996;44:293–5.
123. Boscia JA, Kobasa WD, Knight RA, Abrutyn E, Levison ME, Kaye D. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. *JAMA*. 1987;257:1067–71.
124. Abrutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? *Ann Intern Med*. 1994;120:827–33.
125. Nicolle LE, Bjornson J, Harding GK, MacDonell JA. Bacteriuria in elderly institutionalized men. *N Engl J Med*. 1983;309:1420–5.
126. Nicolle LE, Mayhew WJ, Bryan L. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. *Am J Med*. 1987;83:27–33.
127. Bouvet C, Lübbecke A, Bandi C, Pagani L, Stern R, Hoffmeyer P, et al. Is there any benefit in pre-operative urinary analysis before elective total joint replacement? *Bone Joint J*. 2014;96-B:390–4.
128. Wymenga AB, van Horn JR, Theeuwes A, Muytjens HL, Slooff TJ. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. *Acta Orthop Scand*. 1992;63:665–71.
129. Cordero-Ampuero J, González-Fernández E, Martínez-Vélez D, Esteban J. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. *Clin Orthop Relat Res*. 2013;471:3822–9.
130. Sousa R, Muñoz-Mahamud E, Quayle J, Dias da Costa L, Casals C, Scott P, et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? *Clin Infect Dis*. 2014;59:41–7.
131. Pull ter Gunne AF, Hosman AJF, Cohen DB, Schuetz M, Habil D, van Laarhoven CJHM, et al. A methodological systematic review on surgical site infections following spinal surgery: part 1: risk factors. *Spine (Phila Pa 1976)*. 2012;37:2017–33.
132. Núñez-Pereira S, Pellisé F, Rodríguez-Pardo D, Pigrau C, Sánchez JM, Bagó J, et al. Individualized antibiotic prophylaxis reduces surgical site infections by gram-negative bacteria in instrumented spinal surgery. *Eur Spine J*. 2011;20 Suppl 3:397–402.
133. Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury. *Phys Med Rehabil*

Clin N Am. 2007;18:255–74.

134. D'Hondt F, Everaert K. Urinary tract infections in patients with spinal cord injuries. *Curr Infect Dis Rep*. 2011;13:544–51.
135. Waites KB, Canupp KC, DeVivo MJ. Epidemiology and risk factors for urinary tract infection following spinal cord injury. *Arch Phys Med Rehabil*. 1993;74:691–5.
136. Lewis RI, Carrion HM, Lockhart JL, Politano VA. Significance of asymptomatic bacteriuria in neurogenic bladder disease. *Urology*. 1984;23:343–7.
137. Maynard FM, Diokno AC. Urinary infection and complications during clean intermittent catheterization following spinal cord injury. *J Urol*. 1984;132:943–6.
138. Waites KB, Canupp KC, DeVivo MJ. Eradication of urinary tract infection following spinal cord injury. *Paraplegia*. 1993;31:645–52.
139. Kuhlemeier KV, Stover SL, Lloyd LK. Prophylactic antibacterial therapy for preventing urinary tract infections in spinal cord injury patients. *J Urol*. 1985;134:514–7.
140. Mohler JL, Cowen DL, Flanagan RC. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. *J Urol*. 1987;138:336–40.
141. Green H, Rahamimov R, Goldberg E, Leibovici L, Gafer U, Bishara J, et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. *Eur J Clin Microbiol Infect Dis*. 2013;32:127–31.
142. Pellé G, Vimont S, Levy PP, Hertig A, Ouali N, Chassin C, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. *Am J Transplant*. 2007;7:899–907.
143. Vidal E, Cervera C, Cordero E, Armiñanzas C, Carratalá J, Cisneros JM, et al. Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microb. *Enferm Infecc Microbiol Clin*. 2015;33:680–7.
144. Muñoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. *Clin Infect Dis*. 2001;33 Suppl 1:S53–7.
145. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9 Suppl 3:S1–155.
146. Yacoub R, Akl NK. Urinary tract infections and asymptomatic bacteriuria in renal transplant recipients. *J Glob Infect Dis*. 2011;3:383–9.
147. Snyderman DR. Posttransplant microbiological surveillance. *Clin Infect Dis*. 2001;33 Suppl 1:S22–5.
148. Parasuraman R, Julian K. Urinary tract infections in solid organ transplantation. *Am J Transplant*. 2013;13 Suppl 4:327–36.
149. Coussemont J, Abramowicz D. Should we treat asymptomatic bacteriuria after renal transplantation? *Nephrol Dial Transplant*. 2014;29:260–2.
150. Moradi M, Abbasi M, Moradi A, Boskabadi A, Jalali A. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. *Urol J*. 2005;2:32–5.
151. El Amari EB, Hadaya K, Bühler L, Berney T, Rohner P, Martin P-Y, et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. *Nephrol Dial Transplant*. 2011;26:4109–14.
152. Moysés Neto M, Costa RS, Reis MA, Ferraz AS, Saber LT, Batista ME, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients.

Clin Transplant. 1997;11:446–52.

153. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2015;62:e1–50.

154. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. *Bone Marrow Transplant*. 2009;44:453–558.

155. Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. *Nat Rev Urol*. 2012;9:85–93.

156. Wullt B, Bergsten G, Carstensen J, Gustafsson E, Gebratsedik N, Holst E, et al. Mucosal host responses to bacteriuria in colonic and ileal neobladders. *Eur Urol*. 2006;50:1065–71.

157. Anderton KJ, Abbas AM, Davey A, Ancill RJ. High dose, short course amoxycillin in the treatment of bacteriuria in pregnancy. *Br J Clin Pract*. 1983;37:212–4.

158. Bailey RR, Bishop V, Peddie BA. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. *Aust N Z J Obstet Gynaecol*. 1983;23:139–41.

159. Bailey RR, Peddie BA, Bishop V. Comparison of single dose with a five-day course of trimethoprim for asymptomatic (covert) bacteriuria of pregnancy. *N Z Med J*. 1986;99:501–3.

160. Brumfitt W, Hamilton-Miller JM, Franklin IN, Anderson FM, Brown GM. Conventional and two-dose amoxycillin treatment of bacteriuria in pregnancy and recurrent bacteriuria: a comparative study. *J Antimicrob Chemother*. 1982;10:239–48.

161. Gerstner GJ, Müller G, Nahler G. [Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy--3g single dose versus 3 times 750mg 4-day therapy]. *Zeitschrift für Geburtshilfe und Perinatol*. 1987;191:202–5.

162. Gerstner GJ, Müller G, Nahler G. Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin. *Gynecol Obstet Invest*. 1989;27:84–7.

163. Lumbiganon P, Villar J, Laopaiboon M, Widmer M, Thinkhamrop J, Carroli G, et al. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. *Obstet Gynecol*. 2009;113:339–45.

164. Masterton RG, Evans DC, Strike PW. Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium--a controlled clinical trial. *Br J Obstet Gynaecol*. 1985;92:498–505.

165. Olsen L, Nielsen IK, Zachariassen A, Sederberg-Olsen J, Frimodt-Møller N. Single-dose versus six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy. A prospective randomised study. *Dan Med Bull*. 1989;36:486–7.

166. Pregazzi R, Mazzatenta E, Bouchè C. [Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications]. *Minerva Ginecol*. 1987;39:289–92.

167. Reeves DS. Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy. *J Antimicrob Chemother*. 1975;1:171–86.

168. Bayrak O, Cimentepe E, Inegöl I, Atmaca AF, Duvar CI, Koç A, et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? *Int Urogynecol J Pelvic Floor Dysfunct*. 2007;18:525–9.

169. Estebanez A, Pascual R, Gil V, Ortiz F, Santibáñez M, Pérez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. *Eur J Clin Microbiol Infect Dis*. 2009;28:1457–

64.

170. Thoumsin H, Aghayan M, Lambotte R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. *Infection*. 1990;18 Suppl 2:S94–7.
171. Widmer M, Lopez I, Gülmezoglu AM, Mignini L, Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. *Cochrane database Syst Rev*. 2015;11:CD000491.
172. Zani EL, Clark OAC, Rodrigues Netto N. Antibiotic prophylaxis for transrectal prostate biopsy. *Cochrane database Syst Rev*. 2011;(5):CD006576.
173. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. *Int J Antimicrob Agents*. 2009;34:407–13.
174. McQuiston Haslund J, Rosborg Dinesen M, Sternhagen Nielsen AB, Llor C, Bjerrum L. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. *Scand J Prim Health Care*. 2013;31:235–40.
175. Horton JM. Urinary tract agents: nitrofurantoin, fosfomycin, and methenamine. In: Benett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia: Elsevier; 2015. p. 447–51.
176. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. *Int J Infect Dis*. 2011;15:e732–9.
177. Matsumoto T, Muratani T, Nakahama C, Tomono K. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women. *J Infect Chemother*. 2011;17:80–6.
178. Falagas ME, Vouloumanou EK, Trogias AG, Karadima M, Kapaskelis AM, Rafailidis PI, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. *J Antimicrob Chemother*. 2010;65:1862–77.
179. Ceran N, Mert D, Kocdogan FY, Erdem I, Adalati R, Ozyurek S, et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. *J Infect Chemother*. 2010;16:424–30.
180. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. *Lancet Infect Dis*. 2010;10:43–50.
181. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. *J Antimicrob Chemother*. 2015;70:2456–64.
182. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. *J Antimicrob Chemother*. 1994;33 Suppl A:121–9.
183. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum β -lactamase-producing *Escherichia coli*-related lower urinary tract infection. *Int J Antimicrob Agents*. 2012;40:554–6.
184. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. *Arch Intern Med*. 2007;167:2207–12.
185. Knottnerus BJ, Grigoryan L, Geerlings SE, Moll van Charante EP, Verheij TJM, Kessels AGH, et al. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. *Fam Pract*. 2012;29:659–70.
186. Rafalsky V, Andreeva I, Rjabkova E. Quinolones for uncomplicated acute cystitis in

women. *Cochrane database Syst Rev*. 2006;CD003597.

187. Naber KG, Wullt B, Wagenlehner FME. Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women. *Int J Antimicrob Agents*. 2011;38 Suppl:21–35.

188. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. *JAMA*. 2012;307:583–9.

189. Pigrau C, Espuña M, Fillol M, Pascual MA, Moral E, Muñoz F, Miranda P. Actualización en el diagnóstico y tratamiento de la infección urinaria en la mujer con patología del suelo pélvico. *Guía clínica de la Sección del suelo pélvico de la SEGO; Suelo Pélvico* 2015;11 (supl11):5-17.

190. Cuevas O, Cercenado E, Gimeno M, Marín M, Coronel P, Bouza E. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. *Diagn Microbiol Infect Dis*. 2010;67:251–60.

191. Hooton TM. Recurrent urinary tract infection in women [Internet]. UpToDate. 2015 [cited 2010 Apr 20]. Available from: <http://www.uptodate.com/contents/recurrent-urinary-tract-infection-in-women>.

192. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. *Ann Intern Med*. 1987;106:341–5.

193. Bach D, van den Berg-Segers A, Hübner A, van Breukelen G, Cesana M, Plétan Y. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. *J Urol*. 1995;154:19–24.

194. Israel RS, Lowenstein SR, Marx JA, Koziol-McLain J, Svoboda L, Ranniger S. Management of acute pyelonephritis in an emergency department observation unit. *Ann Emerg Med*. 1991;20:253–7.

195. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB. ED management of acute pyelonephritis in women: a cohort study. *Am J Emerg Med*. 1994;12:271–8.

196. Ward G, Jorden RC, Severance HW. Treatment of pyelonephritis in an observation unit. *Ann Emerg Med*. 1991;20:258–61.

197. Elkharrat D, Chastang C, Boudiaf M, Le Corre A, Raskine L, Caulin C. Relevance in the emergency department of a decisional algorithm for outpatient care of women with acute pyelonephritis. *Eur J Emerg Med*. 1999;6:15–20.

198. Lluís M, Miró O, Perea M, Pedrol E, Mijana M, Rodellar T, et al. Evolución de las pacientes con pielonefritis aguda no complicada tras su atención inicial y alta directa desde un servicio de urgencias hospitalario. *Emergencias*. 2009;21:325–32.

199. Kim K, Lee CC, Rhee JE, Suh GJ, Lee H-J, Kim H Bin, et al. The effects of an institutional care map on the admission rates and medical costs in women with acute pyelonephritis. *Acad Emerg Med*. 2008;15:319–23.

200. Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. *Obstet Gynecol*. 1995;86:560–4.

201. Wing DA, Hendershott CM, Debuque L, Millar LK. Outpatient treatment of acute pyelonephritis in pregnancy after 24 weeks. *Obstet Gynecol*. 1999;94:683–8.

202. Safrin S, Siegel D, Black D. Pyelonephritis in adult women: inpatient versus outpatient therapy. *Am J Med*. 1988;85:793–8.

203. Angel JL, O'Brien WF, Finan MA, Morales WJ, Lake M, Knuppel RA. Acute pyelonephritis in pregnancy: a prospective study of oral versus intravenous antibiotic therapy. *Obstet Gynecol*. 1990;76:28–32.

204. Regalado J, Mendoza H, Aizpuru F, Altuna E, Gómez M, Cía JM. [Acute pyelonephritis treated under "home hospitalization." Ten years' experience]. *Enferm Infecc Microbiol Clin*. 2006;24:629–33.
205. Efstathiou SP, Pefanis A V, Tsioulos DI, Zacharos ID, Tsiakou AG, Mitromaras AG, et al. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. *Arch Intern Med*. 2003;163:1206–12.
206. Wie S-H, Ki M, Kim J, Cho YK, Lim S-K, Lee JS, et al. Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute pyelonephritis: a prospective multicentre study. *Clin Microbiol Infect*. 2014;20:O721–9.
207. Buonaiuto VA, Marquez I, De Toro I, Joya C, Ruiz-Mesa JD, Seara R, et al. Clinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study. *BMC Infect Dis*. 2014;14:639.
208. Shaw E, Benito N, Rodríguez-Baño J, Padilla B, Pintado V, Calbo E, et al. Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: impact of antimicrobial resistance in a large hospitalised cohort. *J Infect*. 2015;70:247–54.
209. Wie S-H, Kim HW, Chang U-I. Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae in elderly and non-elderly women. *Clin Microbiol Infect*. 2014;20:1211–8.
210. Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. *Clin Microbiol Infect*. 2013;19:962–8.
211. Smithson A, Ramos J, Bastida MT, Bernal S, Jove N, Niño E, et al. Differential characteristics of healthcare-associated compared to community-acquired febrile urinary tract infections in males. *Eur J Clin Microbiol Infect Dis*. 2015;34:2395–402.
212. Rodríguez-Baño J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. *Enferm Infecc Microbiol Clin*. 2015;33:337.e1–337.e21.
213. Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. *Eur J Clin Microbiol Infect Dis*. 1990;9:317–23.
214. Bailey RR, Begg EJ, Smith AH, Robson RA, Lynn KL, Chambers ST, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. *Clin Nephrol*. 1996;46:183–6.
215. Moreno-Martínez A, Mensa J, Martínez JA, Marco F, Vila J, Almela M, et al. [Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis]. *Med Clin (Barc)*. 1998;111:521–4.
216. Chang U-I, Kim HW, Wie S-H. Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women. *Antimicrob Agents Chemother*. 2015;59:2488–95.
217. Llor C, Aspiroz C, Cano A, Barranco M. The use of amoxicillin and clavulanic acid and quinolones as first choice antibiotics in uncomplicated urinary tract infections in Spain should be reviewed. *Aten Primaria*. 2012;44:443–4.
218. Bosch P, Falco V, Viñado B, Andreu A, Len O, Almirante B, et al. Impacto de la

- sensibilidad antimicrobiana en el pronóstico de las pielonefritis extrahospitalarias. In: 20th National Conference of The Spanish Society of Infectious Diseases and Clinical Microbiology. Barcelona, Spain; 2016.
219. Bailey RR, Lynn KL, Robson RA, Peddie BA, Smith A. Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. *N Z Med J*. 1992;105:102–3.
 220. Díaz MA, Hernández-Bello JR, Rodríguez-Baño J, Martínez-Martínez L, Calvo J, Blanco J, et al. Diversity of *Escherichia coli* strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. *J Clin Microbiol*. 2010;48:2840–5.
 221. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual A. β -Lactam/ β -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli*: a post hoc analysis of prospective cohorts. *Clin Infect Dis*. 2012;54:167–74.
 222. Singh KP, Li G, Mitrani-Gold FS, Kurtinecz M, Wetherington J, Tomayko JF, et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. *Antimicrob Agents Chemother*. 2013;57:5284–90.
 223. Yamamoto Y, Fujita K, Nakazawa S, Hayashi T, Tanigawa G, Imamura R, et al. Clinical characteristics and risk factors for septic shock in patients receiving emergency drainage for acute pyelonephritis with upper urinary tract calculi. *BMC Urol*. 2012;12:4.
 224. Stamey TA, Govan DE, Palmer JM. The localization and treatment of urinary tract infections: the role of bactericidal urine levels as opposed to serum levels. *Medicine (Baltimore)*. 1965;44:1–36.
 225. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant *Klebsiella pneumoniae* from urine. *Antimicrob Agents Chemother*. 2011;55:5893–9.
 226. van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2015;70:1203–11.
 227. Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, et al. Fosfomycin for treatment of prostatitis: New tricks for old dogs. *Clin Infect Dis*. 2015;61:1141–3.
 228. Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. *Antimicrob Agents Chemother*. 2015;59:5602–10.
 229. Vidal L, Gaftner-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother*. 2007;60:247–57.
 230. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β -Lactam plus aminoglycoside or fluoroquinolone combination versus β -lactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis. *Int J Antimicrob Agents*. 2013;41:301–10.
 231. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane database Syst Rev*. 2014;1:CD003344.
 232. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. *Antimicrob Agents Chemother*. 2010;54:1742–8.
 233. Martínez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, et al.

Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. *Antimicrob Agents Chemother*. 2010;54:3590–6.

234. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. *Otolaryngol Head Neck Surg*. 2007;136:340–7.

235. Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. *J Emerg Med*. 2012;42:612–20.

236. Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. *Ann Allergy Asthma Immunol*. 2014;112:404–12.

237. Romano A, Gaeta F, Poves MFA, Valluzzi RL. Cross-reactivity among beta-lactams. *Curr Allergy Asthma Rep*. 2016;16:24.

238. Frumin J, Gallagher JC. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? *Ann Pharmacother*. 2009;43:304–15.

239. Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. *J Allergy Clin Immunol*. 2015;135:972–6.

240. Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? *Clin Infect Dis*. 2014;59:1113–22.

241. Gleckman R, Bradley P, Roth R, Hibert D, Pelletier C. Therapy of symptomatic pyelonephritis in women. *J Urol*. 1985;133:176–8.

242. Mensa J, Moreno-Martinez A, Martinez J et al. Treatment of acute uncomplicated pyelonephritis (AUP): a randomized trial comparing 7- vs. 14-day therapy. In: Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999. Abstract 613, p. 665. American Society for Microbiology, Washington, DC, USA.

243. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet*. 2015;385:1949–56.

244. de Gier R, Karperien A, Bouter K, Zwinkels M, Verhoef J, Knol W, et al. A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections. *Int J Antimicrob Agents*. 1995;6:27–30.

245. Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylensstierna N, Lannergård A, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. *Lancet*. 2012;380:484–90.

246. Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. *Curr Med Res Opin*. 2007;23:2637–45.

247. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. *Urology*. 2008;71:17–22.

248. Bailey RR, Peddie BA. Treatment of acute urinary tract infection in women. *Ann Intern Med*. 1987;107:430.

249. Karachalios GN. Randomized comparative study of amoxicillin-clavulanic acid and co-trimoxazole in the treatment of acute urinary tract infections in adults. *Antimicrob Agents Chemother*. 1985;28:693–4.
250. Montini G, Toffolo A, Zucchetta P, Dall'Amico R, Gobber D, Calderan A, et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. *BMJ*. 2007;335:386.
251. Kawashima A, Sandler CM, Goldman SM. Imaging in acute renal infection. *BJU Int*. 2000;86 Suppl 1:70–9.
252. Browne RFJ, Zwirewich C, Torreggiani WC. Imaging of urinary tract infection in the adult. *Eur Radiol*. 2004;14 Suppl 3:E168–83.
253. Das CJ, Ahmad Z, Sharma S, Gupta AK. Multimodality imaging of renal inflammatory lesions. *World J Radiol*. 2014;6:865–73.
254. Le Conte P, Simon N, Bourrier P, Merit JB, Lebrin P, Bonnieux J, et al. [Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. *Presse Med*. 2001;(1):11–5.
255. Ortega Enciso L, Sánchez Martínez F, Escape Díaz-Bonilla I, Martínez Montauti J, Bastart Miralles F, Vilà Santasuana A. [Clinical indications for echography in acute pyelonephritis in adult women]. *Rev Clin Esp*. 1998;198:647–50.
256. Peleg AY, MacLaren G, Hoy J. Acute pyelonephritis: management steps that remain unresolved. *Clin Infect Dis*. 2007;45:1249; author reply 1250.
257. Piccoli GB, Consiglio V, Deagostini MC, Serra M, Biolcati M, Ragni F, et al. The clinical and imaging presentation of acute "non complicated" pyelonephritis: a new profile for an ancient disease. *BMC Nephrol*. 2011;12:68.
258. Rollino C, Beltrame G, Ferro M, Quattrocchio G, Sandrone M, Quarello F. Acute pyelonephritis in adults: a case series of 223 patients. *Nephrol Dial Transplant*. 2012;27:3488–93.
259. Lim SK, Ng FC. Acute pyelonephritis and renal abscesses in adults--correlating clinical parameters with radiological (computer tomography) severity. *Ann Acad Med Singapore*. 2011;40:407–13.
260. Nicolle LE. Urinary catheter-associated infections. *Infect Dis Clin North Am*. 2012;26:13–27.
261. Pigrau C. Nosocomial urinary tract infections. *Enferm Infecc Microbiol Clin*. 2013;31:614–24.
262. Warren JW. Catheter-associated urinary tract infections. *Infect Dis Clin North Am*. 1997;11:609–22.
263. Martínez JA, Mensa J. Catheter-related urinary tract infections in the community. *Enferm Infecc Microbiol Clin*. 2005;23 Suppl 4:57–66.
264. Tenke P, Köves B, Johansen TEB. An update on prevention and treatment of catheter-associated urinary tract infections. *Curr Opin Infect Dis*. 2014;27:102–7.
265. Tambyah PA, Oon J. Catheter-associated urinary tract infection. *Curr Opin Infect Dis*. 2012;25:365–70.
266. Gould C V, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Guideline for prevention of catheter-associated urinary tract infections 2009. *Infect Control Hosp Epidemiol*. 2010;31:319–26.
267. Urinary tract infection (catheter-associated urinary tract infection [CAUTI] and non-catheter-associated urinary tract infection [UTI]) and other urinary system infection [USI] events [Internet]. [cited 2012 Jan 1]. Available from:

http://www.cdc.gov/nhsn/PDFs/pscManual/7pscCAUTI_current.pdf

268. Trautner BW. Management of catheter-associated urinary tract infection. *Curr Opin Infect Dis*. 2010;23:76–82.
269. Pigrau-Serrallach C. Recurrent urinary tract infections. *Enferm Infecc Microbiol Clin*. 2005;23 Suppl 4:28–39.
270. Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. *J Infect Dis*. 1982;146:719–23.
271. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. *Am J Infect Control*. 2014;42:1033–8.
272. Alvarez-Lerma F, Gracia-Arnillas MP, Palomar M, Olaechea P, Insausti J, López-Pueyo MJ, et al. Urethral catheter-related urinary infection in critical patients admitted to the ICU. Descriptive data of the ENVIN-UCI study. *Med intensiva / Soc Española Med Intensiva y Unidades Coronarias*. 2013;37:75–82.
273. Raz R, Schiller D, Nicolle LE. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. *J Urol*. 2000;164:1254–8.
274. Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. *Infect Control Hosp Epidemiol*. 2001;22:120–4.
275. Loeb M, Brazil K, Lohfeld L, McGeer A, Simor A, Stevenson K, et al. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial. *BMJ*. 2005;331:669.
276. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. *J Am Paraplegia Soc*. 1992;15:194–204.
277. García Leoni ME, Esclarín De Ruz A. Management of urinary tract infection in patients with spinal cord injuries. *Clin Microbiol Infect*. 2003;9:780–5.
278. Massa LM, Hoffman JM, Cardenas DD. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. *J Spinal Cord Med*. 2009;32:568–73.
279. Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. *Antimicrob Agents Chemother*. 2011;55:3485–90.
280. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β -lactamase-producing Enterobacteriaceae on hospital admission. *Infect Control Hosp Epidemiol*. 2013;34:385–92.
281. Pascual A, Pintado V, Rodríguez-Baño J, Miró JM. Carbapenemase-producing Enterobacteriaceae: the end of the antibiotic era? *Enferm Infecc Microbiol Clin*. 2014;32 Suppl 4:1–3.
282. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. *Int J Antimicrob Agents*. 2008;31 Suppl 1:S68–78.
283. Dow G, Rao P, Harding G, Brunka J, Kennedy J, Alfa M, et al. A prospective,

randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. *Clin Infect Dis*. 2004;39:658–64.

284. Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2014;34:845–57.

285. Conway LJ, Larson EL. Guidelines to prevent catheter-associated urinary tract infection: 1980 to 2010. *Heart Lung*. 2012;41:271–83.

286. Rebmann T, Greene LR. Preventing catheter-associated urinary tract infections: An executive summary of the Association for Professionals in Infection Control and Epidemiology, Inc, Elimination Guide. *Am J Infect Control*. 2010;38:644–6.

287. Marschall J, Carpenter CR, Fowler S, Trautner BW. Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis. *BMJ*. 2013;346:f3147.

288. Pigrau C. Infecciones urinarias recurrentes: factores predisponentes y estrategias de prevención. In: Pigrau C, editor. *Infección del tracto urinario*. Madrid: Ergon. 2013. p. 85–104.

289. Geerlings SE, Beerepoot MAJ, Prins JM. Prevention of recurrent urinary tract infections in women: antimicrobial and nonantimicrobial strategies. *Infect Dis Clin North Am*. 2014;28:135–47.

290. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. *J Infect Dis*. 2000;182:1177–82.

291. Smith HS, Hughes JP, Hooton TM, Roberts P, Scholes D, Stergachis A, et al. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. *Clin Infect Dis*. 1997;25:63–8.

292. Engel G, Schaeffer AJ, Grayhack JT, Wendel EF. The role of excretory urography and cystoscopy in the evaluation and management of women with recurrent urinary tract infection. *J Urol*. 1980;123:190–1.

293. Fair WR, McClennan BL, Jost RG. Are excretory urograms necessary in evaluating women with urinary tract infection? *J Urol*. 1979;121:313–5.

294. Fairchild TN, Shuman W, Berger RE. Radiographic studies for women with recurrent urinary tract infections. *J Urol*. 1982;128:344–5.

295. Fowler JE, Pulaski ET. Excretory urography, cystography, and cystoscopy in the evaluation of women with urinary-tract infection: a prospective study. *N Engl J Med*. 1981;304:462–5.

296. Jackson SL, Boyko EJ, Scholes D, Abraham L, Gupta K, Fihn SD. Predictors of urinary tract infection after menopause: a prospective study. *Am J Med*. 2004;117:903–11.

297. Castelló T, Girona L, Gómez MR, Mena Mur A, García L. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. *Spinal Cord*. 1996;34:592–3.

298. Lee BSB, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. *Cochrane database Syst Rev*. 2012;10:CD003265.

299. Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. *J Urol*. 1999;161:207–11.

300. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. *Ann Intern Med*. 2001;135:9–16.

301. Wong ES, McKevitt M, Running K, Counts GW, Turck M, Stamm WE. Management of recurrent urinary tract infections with patient-administered single-dose therapy. *Ann Intern Med*. 1985;102:302–7.

302. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. *Cochrane database Syst Rev*. 2004;(3):CD001209.
303. Sen A. Recurrent cystitis in non-pregnant women. *BMJ Clin Evid*. 2008 Jan;2008.
304. Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. *Arzneimittelforschung*. 2005;55:420–7.
305. Cetti RJ, Venn S, Woodhouse CRJ. The risks of long-term nitrofurantoin prophylaxis in patients with recurrent urinary tract infection: a recent medico-legal case. *BJU Int*. 2009;103:567–9.
306. Grayson M, Whitby M. Nitrofurans: Nitrofurazone, furazolidone and nitrofurantoin. In: Kucer's The use of antibiotics. 6th edition. London: Edward Arnold; 2010. p. 1195–204.
307. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. *J Urol*. 1997;157:935–9.
308. Beerepoot MAJ, ter Riet G, Nys S, van der Wal WM, de Borgie CAJM, de Reijke TM, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. *Arch Intern Med*. 2011;171:1270–8.
309. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. *Cochrane database Syst Rev*. 2012;10:CD001321.
310. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. *Cochrane database Syst Rev*. 2008;(1):CD001321.
311. Wang C-H, Fang C-C, Chen N-C, Liu SS-H, Yu P-H, Wu T-Y, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012;172:988–96.
312. McMurdo MET, Argo I, Phillips G, Daly F, Davey P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. *J Antimicrob Chemother*. 2009;63:389–95.
313. Howell AB, Botto H, Combescure C, Blanc-Potard A-B, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic *Escherichia coli* anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. *BMC Infect Dis*. 2010;10:94.
314. Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, et al. Recurrent urinary tract infections in postmenopausal women. *Clin Infect Dis*. 2000;30:152–6.
315. Ikäheimo R, Siitonen A, Heiskanen T, Kärkkäinen U, Kuosmanen P, Lipponen P, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. *Clin Infect Dis*. 1996;22:91–9.
316. Hu KK, Boyko EJ, Scholes D, Normand E, Chen C-L, Grafton J, et al. Risk factors for urinary tract infections in postmenopausal women. *Arch Intern Med*. 2004;164:989–93.
317. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane database Syst Rev*. 2008;(2):CD005131.
318. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med*. 1993;329:753–6.
319. Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the

prevention of recurrent urinary tract infection in postmenopausal women. *Clin Infect Dis*. 2003;36:1362–8.

320. Naber KG, Cho Y-H, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. *Int J Antimicrob Agents*. 2009;33:111–9.

321. Taha Neto KA, Nogueira Castilho L, Reis LO. Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-analysis. *Actas Urol Esp*. 2016;40:203–8.

322. Barrons R, Tassone D. Use of *Lactobacillus* probiotics for bacterial genitourinary infections in women: a review. *Clin Ther*. 2008;30:453–68.

323. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. *World J Urol*. 2014;32:79–84.

Annex 1

Level of scientific evidence	
I	Evidence obtained from ≥ 1 randomized clinical trial
II	Evidence obtained from ≥ 1 well-designed non-randomized clinical trial, or cohort studies, or case-control-studies, especially if they have been performed in more than one centre.
III	Evidence obtained from documents or opinions of experts, based in clinical experience or case series
Grades of recommendation	
A	Good evidence to recommend the use of a measure or practice
B	Moderate evidence to recommend the use of a measure or practice
C	Poor evidence to recommend the use of a measure or practice
D	Moderate evidence to discourage the use of a measure or practice
E	Good evidence to discourage the use of a measure or practice

Tables

Table 1
Serum and urine PK/PD indices of oral antibiotics against *E.coli* in acute uncomplicated cystitis

Fir st ch oi c e	Do se (m g)	C _{max} (mg/L)	Fu (%)	Pr ote in bin din g (%)	Uri nar y C _{ma} x (m g/L)	EU CA ST bre ak poi nts ⁵² (m g/L)	<i>E. coli</i> MI C ₉₀ (m g/L) [*]	Urinary C _{max} /MIC ₉₀
Fos fo my cin tro me ta mo l	300 0 SD	22-32	32-43 (48h)	<5	441 5	≤32	32	138
Nit rof ura nto in	100 q12 h	1	30-40	90	200	≤64	32	6.25

Alternatives								
Ciprofloxacin	500 q12 h	2-3	40-50	30	200	≤0.5	4	50
Cefuroxime axetil	500 q12 h	4.4-9.9	32	40	160	≤8	8	20
Amoxicillin-clavulanic acid	500 /125 q8h	8/4	75/60	20/22	>500	≤32	16/8	31.25

Data from Mazzei et al⁵⁶.

Fu: Fraction unbound.

*MIC values of 781 isolates from female outpatients in Álava, aged between 15 and 65 years with acute urinary tract infections (Canut A, personal communication).

Table 2Serum PK/PD indices for parenteral antibiotics against *E.coli* in acute pyelonephritis

	Dose (mg)	EUCAST breakpoin ts ¹⁶ (mg/L)	<i>E. coli</i> MIC ₉₀ (mg/L) *	Probability of target attainment (PTA) ≥90%				
				AUC _{0-24h} /MIC ≥125	% <i>f</i> T>MIC ≥50	% <i>f</i> T>MIC ≥70	% <i>f</i> T>MIC ≥40	C _{max} /MIC ≥10
Ciprofloxacin	400 q12h	≤0.5	4	If MIC ≤0.12 mg/L				
Levofloxacin	500 q24h	≤1	2	If MIC ≤0.25 mg/L				
Ceftriaxone**	1,000 q24h	≤1	1			If MIC ≤0.5 mg/L		
Piperacillin-tazobactam	4,500 q6h	≤8	16/4		If MIC ≤4 mg/L			
Meropenem	1,000 q8h	≤2	1				If MIC ≤2 mg/L	
Gentamicin	5/kg q24h	≤2	4					If MIC ≤2 mg/L

Adapted from Frei et al⁵⁸.

*MIC values of 781 isolates from female outpatients in Álava, aged between 15 and 65 years with acute urinary tract infections (Canut A, personal communication).

**After improvement, the patient may be switched to oral cefixime (EUCAST breakpoint ≤1 mg/L). *f*T>MIC ≥70%, if MIC ≤0.25 mg/L (200 mg q12h). *f*T>MIC ≥70%, if MIC ≤0.06 mg/L (400 mg q24h).

Table 3

Treatment of asymptomatic bacteriuria during pregnancy

Reference (year)	Design	Antimicrobial therapy	Bacteriological eradication Number of patients with eradication of bacteriuria / total number of patients (%)		Pyelonephritis Number of patients with pyelonephritis / total number of patients (%)		
			Pregnant women with treated BA	Pregnant women with untreated AB	Pregnant women without AB	Pregnant women with AB	Pregnant women with untreated AB
Brumfitt W (1975) ⁶⁸	Randomized, placebo- controlled	Sulfonamide vs. placebo	-----	-----	3/150 (2)	4/67 (6)	55/179 (31)
Elder HA <i>et al</i> (1966) ⁶⁹	Randomized, placebo- controlled	Sulfasymazine vs. placebo	40/52 (76.9)	19/49 (38.8)	-----	-----	7/52 (13.5)
Elder EH <i>et al</i> (1971) ⁷⁰	Alternating, placebo- controlled	Tetracycline vs. placebo	100/133 (75.2)	47/145 (32.4)	2/279 (0.7)	4/133 (3)	27/148 (18)
Foley ME <i>et al</i> (1987) ⁷¹	Randomized	Sulphamethizole or nitrofurantoin vs. non- treatment	73/100 (73)	58/120 (48)	-----	3/100 (3)	3/120 (2.5)
Furness ET <i>et al</i> (1975) ⁷²	Randomized	Methenamine mandelate or methenamine hippurate vs. non-treatment	-----	-----	150/5,030 (3)	23/139 (16.5)	17/67 (25.4)
Gold EM <i>et al</i> (1966) ⁷³	Randomized, placebo- controlled	Sulfadimethoxine or sulfadiazine vs. placebo	23/35 (65.7)	8/30 (26.6)	-----	0/35 (0)	4/30 (13.3)

Kincaid –Smith O, Bullen M (1965) ⁷⁴	Cohort, sequential	Sulphamethoxydiazine or sulphadimidine vs placebo	42/51 (82.3)	32/50 (64)	48/4,000 (1.2)	2/61 (3.3)	20/55 (36.6)
Little PJ (1966) ⁷⁵	Randomized, placebo-controlled	Sulphonamide or nitrofurantoin vs placebo	-----	-----	19/4,735 (0.4)	4/124 (3.2)	35/141 (25)
Pathak UN <i>et al</i> (1969) ⁷⁶	Placebo-controlled	Nitrofurantoin vs placebo	73/76 (96.1)	27/76 (35.5)	8/729 (1.1)	3/76 (4)	17/76 (22.4)
Williams GL <i>et al</i> (1969) ⁷⁷	Randomized	Sulphadimidine, nitrofurantoin or ampicillin vs non-treatment	-----	-----	-----	5/85 (6)	18/78 (23)
Wren BG (1969) ⁷⁸	Alternating	Nitrofurantoin, ampicillin, sulphafurazol, nalidixic acid vs non-treatment	70/83 (84.3)	3/90 (3.3)	-----	3/83 (3.6)	33/90 (37)
Savage <i>et al</i> (1967) ⁷⁹	Alternating, placebo-controlled	Sulfonamide vs placebo	-----	-----	7/496 (1.4)	1/93 (1.1)	26/98 (26)
LeBlanc AL, McGanity WJ (1964) ⁸⁰	Randomized, not blinded	Sulfamethizole and mandelamine or nitrofuradantoin or mandelamine alone vs non-treatment	-----	-----	22/1,143 (1.9)	3/69 (4.3)	8/41 (20)
Kazemier BM <i>et al</i> (2015) ⁸¹	Cohort prospective Randomized, placebo-controlled	Nitrofurantoin vs non-treatment or placebo	-----	-----	24/4,035 (0.6)	1/40 (2.6)	5/208 (2.4)

Table 4

Comparative study of antibiotic treatment of asymptomatic bacteriuria in pregnancy (single dose versus short course of 4-7 days).

Same antimicrobial agent

Reference (year)	Design	Participants (1,378)	Antimicrobial therapy	Bacteriological eradication (%)	Recurrent AB (%)	Side effects (%)
Anderton KJ <i>et al</i> (1983) ¹⁵⁷	Alternating	64	- Amoxicillin 3 g × 2 doses during 1 day - Amoxicillin 250 mg 3 times daily × 7 days	21/33 (63.6) 31/34 (91.2)	-----	1/33 (3) 1/34 (2.9)
Bailey RR <i>et al</i> (1983) ¹⁵⁸	Randomized	44	- Co-trimoxazole 1.92 g × 1 dose - Co-trimoxazole 0.96 g twice daily × 5 days	18/21 (85.7) 20/20 (100)	7/24 (29.2) 2/18 (11.1)	0/24 (0) 0/20 (0)
Bailey RR <i>et al</i> (1986) ¹⁵⁹	Randomized	60	- Trimethoprim 600 mg × 1 dose - Trimethoprim 300 mg once daily × 5 days	27/30 (90) 24/30 (80)	6/30 (20) 5/30 (16.7)	1/30 (3.3) 0/30 (0)
Brumfitt W <i>et al</i> (1982) ¹⁶⁰	Randomized	54	- Amoxicillin 3 g × 2 doses during 1 day - Amoxicillin 250 mg 3 times daily × 7 days	19/29 (65.5) 16/24 (66.7)	1/29 (3.4) 1/24 (4.2)	3/29 (10.3) 4/24 (16.7)
Gerstner GJ <i>et al</i> (1987-89) ^{161,162}	Randomized	91	- Amoxicillin 3 g × 1 dose - Amoxicillin 750 mg 3 times daily × 4 days	41/53 (77.3) 23/37 (62.2)	11/46 (23.9) 9/29 (31)	2/53 (3.8) 5/37 (13.5)
Lumbiganon P <i>et al</i> (2009) ¹⁶³	Randomized	778	- Nitrofurantoin 100 mg × 2 doses during 1 day - Nitrofurantoin 100 mg twice daily × 7 days	281/371 (75.7) 319/370 (86.2)	-----	75/375 (20) 90/385 (23.4)
Masterton RG <i>et al</i> (1985) ¹⁶⁴	Randomized	102	- Amoxicillin 3 g × 1 dose - Ampicillin 500 mg 4 times daily × 7 days	33/39 (84.6) 20/23 (86.9)	-----	-----
Olsen L <i>et al</i> (1989) ¹⁶⁵	Randomized	41	- Sulfamethizole 2 g × 1 dose - Sulfamethizole 1 g twice daily × 6 days	8/15 (53.3) 20/24 (83.3)	7/15 (46.7) 11/24 (45.8)	3/15 (20) 6/24 (25)
Pregazzi R <i>et al</i> (1987) ¹⁶⁶	Randomized	44	- Amoxicillin 3 g, or ampicillin 3.5 g, or trimethoprim 320 mg, or sulfamethoxazole 1600 mg, or cephalexin 3 g, × 1 dose - The same antibiotics 2-4 times daily ×	12/22 (54.5) 19/22 (86.4)	8/22 (36.4) 6/22 (27.3)	4/22 (18.2) 6/22 (27.3)

			7days			
Reeves DS <i>et al</i> (1975) ¹⁶⁷	Alternating	100	- Sulfonamide sulfametopyrazine 2 g × 1 dose - Sulfadimidine 4 times daily × 7 days	37/49 (75.5) 25/40 (62.5)	-----	6/47 (12.8) 13/40 (32.5)

Different antimicrobial agents

Reference (year)	Design	Participants (244)	Antimicrobial therapy	Bacteriological eradication (%)	Recurrent AB (%)	Side effects (%)
Bayrak O <i>et al</i> (2007) ¹⁶⁸	Randomized	90	- Fosfomycin trometamol 3 g × 1 dose - Cefuroxime Axetil 250 mg twice daily × 5 days	41/44 (93.2) 38/40 (95)	-----	1/44 (2.3) 2/40 (5)
Estebanez A <i>et al</i> (2009) ¹⁶⁹	Randomized	131	- Fosfomycin trometamol 3 g × 1 dose - Amoxicillin-clavulanate 500 mg/125 mg 3 times daily × 7 days	44/53 (83) 45/56 (80.3)	1/53 (1.9) 1/56 (1.8)	1/53 (1.9) 11/56 (19.6)
Thoumsin <i>et al</i> (1990) ¹⁷⁰	Randomized	23	- Fosfomycin trometamol 3 g × 1 dose - Nitrofurantoin 100 mg twice daily × 7 days	11/13 (84.6) 9/10 (90)	2/13 (15.4) 1/10 (10)	0/13 (0) 2/10 (20)

Table 5

Effectiveness and side effects of therapeutic regimens in acute uncomplicated cystitis^a

Antibiotic	Dose, duration	Clinical efficacy % (range)	Microbiological efficacy % (range)	Common side effects
Fosfomycin trometamol	3-g single dose	91	80 (78-83)	Diarrhea, nausea, headache
Nitrofurantoin macrocrystals	50-100 mg qid, 5-7 days	93 (84-95)	88 (86-92)	Nausea, headache
Fluoroquinolones ^b	Dose varies, 3 days	90 (85-98)	91 (81-98)	Nausea, vomiting, diarrhea, headache, drowsiness, insomnia
Beta-lactams ^c	Dose varies, 3-5 days	89 (79-98)	82 (74-98)	Diarrhea, nausea, vomiting, rash, urticaria, vaginal candidiasis
Trimethoprim-sulfamethoxazole ^d	160/800 mg bid, 3 days	93 (90-100)	94 (91-100)	Rash, urticaria, nausea, vomiting, hematologic

bid: Twice daily; qid: Four times daily.

^aModified from Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update for the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120, by permission of Oxford University Press.

^bData on fluoroquinolones applies to regimens of ciprofloxacin, levofloxacin, norfloxacin and ofloxacin.

^cData on beta-lactams is compiled from clinical trials examining second- and third-generation cephalosporins and amoxicillin-clavulanate (5 days).

^dEfficacy data when resistance rate of *E. coli* to trimethoprim-sulfamethoxazole is <20%.

Table 6

Summary of the studies of antimicrobial therapy of acute uncomplicated cystitis in non-pregnant women, from January 2010 to June 2016

First author, year ^{ref}	Study design, Location	Study population	Study drugs (dosage, duration)	Follow-up			Adverse events ^d %	Quality assessment	Comments
				Early clinical cure ^a	Late clinical cure ^b	Bacteriologic cure ^c			
Hooton, 2013 ⁴³	Randomized, double-blind, noninferiority, clinical trial, United States	Women, aged 15-55 years with acute uncomplicated cystitis, 300 patients studied	Cefpodoxime 100 mg bid, 3 days vs Ciprofloxacin 250 mg bid, 3 days	88%	82% - 71%	81%	23%	(++)	Cefpodoxime compared with ciprofloxacin did not meet criteria for noninferiority in achieving clinical cure in an intention-to-treat analysis. 40% of women in the cefpodoxime group and 16% in the ciprofloxacin group had vaginal <i>E. coli</i> colonization at first follow-up visit
Matsumoto, 2011 ¹⁷⁷	Open label, observational study, Japan	Women, aged ≥ 20 years, with acute cystitis. 48 patients studied, 64% were premenopausal	Fosfomycin calcium, 1 g tid, 2 days	92%	95.5%	96%	5%	(-)	A non-randomized trial with a small sample. Efficacy evaluated per protocol. No statistical comparisons among the different subgroups of the study. Dropout rate of 19%
Ceran, 2010 ¹⁷⁹	Randomized, single-blind	Women, aged 18- 65 ys, with acute cistitis,	Fosfomycin trometamol	83%		83%	4%	(+)	A single 3 g dose of fosfomycin was as efficient as 5-day

clinical trial, Turkey	142 patients studied	3 g single- dose vs Ciprofloxacin, 500 mg bid., 5 days	81%	81%	3%	ciprofloxacin. Small sample size. Not double- blinded.
---------------------------	-------------------------	---	-----	-----	----	--

bid: Twice daily; tid: Three times daily.
(++) High quality study. Little risk of bias. (+) Acceptable quality study, moderate risk of bias. (-) Poor quality study. High risk of bias.
a. Early clinical cure: Absence of urinary symptoms 5-9 days after the last dose of antimicrobials.
b. Late clinical cure: Absence of urinary symptoms 28-30 days after the last dose of antimicrobials.
c. Bacteriological cure: Absence of bacteriuria 7-10 days after the last dose of antimicrobial.
d. Adverse events were usually mild and did not involve interruption of study medication.

Table 7

Antimicrobial agents for the treatment of acute uncomplicated cystitis: Dosages and duration of therapy

Drug	Dosage	Duration (days)
Fosfomycin trometamol	3 g single dose	Single dose
Fosfomycin calcium ^a	1 g tid	2
Nitrofurantoin macrocrystals	50-100 mg qid*	5-7
Ciprofloxacin	250- 500 mg bid	3
Levofloxacin	250-500 mg once	3
Norfloxacin	400 mg bid	3
Ofloxacin	200 mg bid	3
Amoxicillin-clavulanate	500/125 mg tid	5
Cefuroxime axetil	250-500 mg bid	5
Cefaclor	250 mg tid	5
Cefixime	400 mg once	3
Cefpodoxime-proxetil	100 mg bid	3
Ceftibuten	400 mg once	5
Trimethoprim-sulfamethoxazole	160/800 mg bid	3
Trimethoprim ^b	100 mg bid	3

Data obtained from different studies^{1,21,176,179,182,184,187}.

bid: Twice daily; qid: Four times daily; tid: Thrice daily.

a. Dose and duration taken from reference¹⁷⁷.

b. Trimethoprim is commercialized in Spain as 160 mg tablets.

*Administer with meals. Manufacturer's labeling in Spain recommends 100 mg every 8 hours.

Table 8

Antibiotic resistance in community-acquired versus healthcare-associated non-nosocomial APN due to Enterobacteriaceae

Antibiotic	Community adquired APN (n = 328)*	Health-care associated APN (n = 61)*	P
Ampicilin	248 (75.6)	54 (88.5)	P = 0,029
Amoxicillin- clavulanic acid	73 (22.3)	27 (44.3)	P = 0,001
Piperacillin- tazobactam	59 (18)	27 (44.3)	P = 0,002
Cefuroxime	30 (9.2)	20 (33.3)	P <0,001
Cefotaxime	17 (5.3)	15 (24.6)	P <0,001
Imipenem	0 (0)	0 (0)	
Amikacin	8 (2.4)	2 (3.2)	NS (P = 1)
Ciprofloxacin	73 (22.4)	40 (65.6)	P <0,001
Cotrimoxazole	107 (32.6)	32 (52.5)	P = 0,005
Fosfomycin	9 (2.7)	8 (13.2)	P = 0,01

Data presented as absolute numbers (percentages). Data is from a tertiary hospital in Spain during 2014 (Vall d'Hebron University Hospital)²¹⁸.

*Data includes only Enterobacteriaceae (*E. coli*, *K. pneumoniae*, *Proteus* spp) representing the etiology of 91.3% of community-acquired APN and 65.6% of healthcare-associated APN.

Table 9

Antibiotic resistance in APN patients, taking into account all isolated microorganisms (n = 316) and *Escherichia coli* (n = 260), as well as complicated APN and sex

Antibiotic	Uncomplicated APN		Complicated APN			
	All microorganis ms (n = 117)	<i>E.coli</i> (n = 110)	All microorganisms (n = 199)		<i>E. coli</i> (n = 150)	
			Women (n = 93)	Men (n = 106)	Women (n = 81)	Men (n = 69)
Amoxicillin-clavulanate	23 (19.7)	23 (20.9)	24 (25.8)	30 (28.3)	23 (28.4)	16 (23.2)
Piperacillin-tazobactam	2 (1.7)	2 (1.8)	3 (3.2)	4 (3.8)	2 (2.5)	1 (1.4)
Cefuroxime	13 (11.1) ^a	12 (10.9) ^b	20 (21.5) ^a	21 (20)	18 (22.2) ^b	9 (13)
Ceftriaxone	3 (2.6)	2 (1.8)	4 (4.3)	8 (7.5)	4 (4.9)	2 (2.9)
Imipenem	0	0	1 (1.1)	1 (0.9)	0	0
Gentamicin	9 (7.7)	8 (7.3)	6 (6.5)	16 (15.1)	5 (6.2)	9 (13)
Ciprofloxacin	18 (15.4) ^c	18 (16.4) ^d	24 (25.8) ^c	31 (29.2)	23 (28.4) ^d	18 (26)
Cotrimoxazole	36 (30.8)	36 (32.7)	38 (41)	37 (34.9)	36 (44.4)	23 (33.3)
Nitrofurantoin	13 (11.1)	12 (10.9)	9 (9.7)	16 (15.1)	7 (8.6)	6 (8.7)
Fosfomycin	5 (4.3)	2 (1.8)	6 (6.5)	5 (4.7)	5 (6.2)	1 (1.4)

^ap = 0,04.

^bp = 0,03.

^cp = 0,01.

^dp = 0,04.

Data presented as absolute numbers (percentage). Data comes from a tertiary hospital in Spain between 2009 and 2014 (University Hospital of Álava).

Table 10

Daily dosages for adults with acute pyelonephritis and normal renal function

Antibiotic	Dosage	Observation
Amoxicillin-clavulanic acid*	1-2/0,25 g / 8 h iv 875-125 mg / 8 h oral	• Avoid in patients allergic to penicillins
Cefuroxime sodium	750-1,500 mg / 8 h iv	
Cefuroxime axetil*	0,5 g vo / 8-12 h oral	• Better absorption with meals
Ceftibuten*, cefixime*	0,4 g / 12-24 h oral	• Higher dose until improvement • Low dosage best suited for mild uPNA
Piperacillin-tazobactam	4 g-0.5 g / 6-8 h iv	Higher dose in severe sepsis or in <i>P. aeruginosa</i> Avoid in patients allergic to penicillins
Cefotaxime	1-2 g / 8 h iv	• Higher dose for patients with severe sepsis
Ceftriaxone	1-2 g / 24 h iv	• Higher dose for patients with severe sepsis
Ceftazidime, cefepime	1-2 g / 8 h iv	• Higher dose in severe sepsis or in <i>P. aeruginosa</i>
Ceftolozane-tazobactam	1-0.5 g / 8 h iv	
Aztreonam	1-2 g / 8 h iv	• Higher dose in severe sepsis or in <i>P. aeruginosa</i>
Ertapenem	1 g / 24 iv	
Imipenem	0,5 g / 6 h iv to 1 g / 8 h iv	
Meropenem	0,5-2 g / 8 h iv	• Higher dose in severe sepsis or in <i>P. aeruginosa</i>
Fosfomycin sodium	4-8 g / 8 h iv	
Gentamicin, tobramycin, netilmicin	3-5 mg/kg/d as a single daily dose	• Higher dose for patients with severe sepsis
Amikacin	15-20 mg/kg/d as a single daily dose	• Higher dose for patients with severe sepsis
Ciprofloxacin	200-400 mg / 8- 12 h iv 500-750 mg / 12 h oral	• Higher dose in severe sepsis or in <i>P. aeruginosa</i>
Levofloxacin	500-750 mg / 24 h oral or iv	• Higher dose in severe sepsis or in <i>P. aeruginosa</i>
Trimethoprim-sulfamethoxazole	160-800 mg / 12 h oral or iv	• Best suited for targeted therapy after improvement

iv: intravenous.

*Oral therapy may fail to eradicate the infection with susceptible isolates with MIC values near the breakpoint because PK/PD values are not attained. Higher doses are recommended.

Table 11

Prophylactic antibiotics for prevention of recurrent urinary tract infections

Continuous prophylaxis		Post-coital prophylaxis
Co-trimoxazole	40/200 mg once daily	40/200 mg once 80/400 mg once
Trimethoprim	100 mg once daily	100 mg once
Nitrofurantoin	50-100 mg once daily	50-100 mg once
Ciprofloxacin	125 mg once daily	125 mg once
Norfloxacin	200 mg once daily	200 mg once
Ofloxacin	--	100 mg once
Cefalexin	125-250 mg once daily	125-250 mg once
Cefaclor	250 mg once daily	--
Fosfomycin-trometamol	3 g every 7-10 days	--
Fosfomycin calcium	--	500 mg once

Due to its ecological impact, prophylaxis with fluoroquinolones should be used only when no other preventive strategy is available.